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The Burden of Hypoglycemia during  
Real-World Conditions 
 
Felix Aberer, MD; Andrea Groselj-Strele, PhD; Slave Trajanoski, MD; Tina Pöttler, MS;  
Lisa Knoll, MS; Monika Cigler, MD; Hesham Elsayed, MD;  
Daniel Hochfellner, MD; Julia K Mader, MD, PhD 
 
Medical University of Graz 




Although management of type 1 diabetes (T1D) has improved with the introduction of novel insulins and modern 
technology, hypoglycemia is still a common problem. Little is known about real-world data on hypoglycemia in 
people with T1D using the flash glucose monitoring (FGM). The aim of the present analysis is to assess the 
occurrence of hypoglycemia in a registry of T1D over the course of a year. 
  
Method: 
We analyzed registry data collected at a tertiary diabetes center. Adult patients with T1D routinely using FGM and 
with sensor coverage >80% of time were eligible for analysis. Episodes of hypoglycemia (<3.9mmol/L and 
<3.0mmol/L) and duration of hypoglycemia detected by FGM were determined. Hypoglycemic episodes were 
defined as follows: beginning of the FGM event – readings below the threshold for at least 15 min; end of the FGM 
event - readings for 15 min >3.9 mmol/L; prolonged hypoglycemic event - FGM levels are <3.0 mmol/L for 
consecutive 120 min or more. Additionally, time below range <3.9 mmol/L (TBR), time in range 3.9-10.0 mmol/L 
(TIR) and time above range >10.0 mmol/L (TAR) were analyzed for the population. 
  
Result:  
N=44 patients (36.7% female, mean age: 39.7 ± 14.4 years, diabetes duration 15.5 ± 12.4 years, 100% Caucasian, 
BMI 24.4 ± 3.6 kg/m², A1c 59 ± 11 mmol/mol, insulin pump vs. injection therapy: 13.6%. vs. 77.3%, 9.1% used 
both delivery methods during the observational period) were included in the analysis. Mean observation period was 
13.7 ± 4.6 months. Mean number of hypoglycemic episodes <3.9mmol/L and <3.0mmol/L during the observation 
period was 221.7 ± 143.4 and 93.5 ± 99.1, respectively. Mean duration per hypoglycemic episodes <3.9mmol/L and 
<3.0mmol/L was 50.8 ± 32.2 and 76.2 ± 63.8 minutes, respectively. TAR, TIR and TBR were 40.3 ± 19.1%, 53.9 ± 
17.5% and 5.1 ± 4.3%, respectively. 
  
Conclusion:  




A398 Journal of Diabetes Science and Technology 15(2)DTM 2020 Abstracts  A2 
 
Creating Virtual Simulation Scenarios that 
Mimic Clinical Data Acquired from Patients 
with Type 1 Diabetes  
 
Sayyar Ahmad, MS; Charrise Mary Ramkissoon, PhD; Josep Vehi, PhD; Marga Giménez, MD, 
PhD; Ignacio Conget MD, PhD; Clara Viñals MD 
 





The objective of this research work is to replicate real-life scenarios encountered by patients with type 1 diabetes 
(T1D)  and high glycemic variability to challenge newly-developed controllers.  
 
Method: 
The real-life meal scenario, basal insulin, and bolus insulin were extracted from Medtronic 670G insulin pump 
(Northridge, CA, USA) data for a cohort of N=14 patients with T1D from the Hospital Clínic de Barcelona and 
incorporated into the simulator. Next, using a detection algorithm, disturbances from the clinical data were added to 
the scenario in the form of aerobic exercise. A duration of 14 days was used for generating the scenario using the 
UVA/Padova simulator. The insulin sensitivity and the variability in insulin sensitivity were adjusted day-by-day to 
achieve a blood glucose profile and a coefficient of variation (CV) for the clinical data, respectively.  
 
Result: 
The simulator results obtained replicated clinical data outcomes with an error of less than 10%. The main parameters 
considered were median value of glucose concentration and CV. The median value of glucose reflects the glucose 
profile of the patients and the CV indicates the variability in glucose values. Good approximations of time-in-range 
were also achieved. 
 
Conclusion: 
The methodology used in this work appears to be capable of creating realistic scenarios that mimic real life behavior 
in order to produce data similar to clinical outcomes for a specific population of patients with T1D. This enables 
controllers aimed at optimizing blood glucose in T1D patients to be tested using difficult real-life scenarios thus, 
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In-silico Insulin Estimation Using an 
Extended Kalman Filter  
 
Eleonora M. Aiello, PhD; Kelilah L. Wolkowicz, PhD; Francis J. Doyle, III, PhD; Eyal Dassau, PhD 
  
Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, 




The availability of insulin concentration measurements from an immunosensor may enhance glucose control and the 
automation of automated insulin dosing (AID) systems. The aim of this work is to assess the ability of an Extended 
Kalman Filter to estimate the postprandial excursions of capillary insulin concentration from baseline levels at 
mealtime with different measurement intervals. 
   
Method: 
We propose a nonlinear discrete-time observer based on an insulin pharmacokinetic model augmented with a 
capillary compartment, for which the plasma insulin elimination rate follows Michaelis–Menten kinetics. In order to 
evaluate the observer performance, the estimated excursions from baseline were compared to the excursions 
obtained by a microneedle insulin immunosensor and laboratory-based ELISA insulin measurements of four adults 
with type 1 diabetes (T1D) (mean age: 43±12 years). Using the UVA/Padova Simulator, we evaluated the observer 
across ten subjects with measurement samples occurring at 5-, 30-, 60-, 120-, and 180-minute intervals, using the 
immunosensor noise standard deviation of 20.64 pmol/L. 
 
Result:  
The prediction errors of the observer were determined by assessing the concordance between the estimated and the 
measured insulin differences, which were obtained by comparing the postprandial insulin measurements to the 
mealtime measurement. The median root-mean-square errors between the estimated delta insulin values and the 
immunosensor and ELISA delta changes were 22.47, 10.90, 9.65, 9.87, 10.64, 12.01 pmol/L and 22.11, 14.52, 
14.18, 14.20, 15.18, 16.35 pmol/L for each measurement interval, respectively.  
 
Conclusion:  
We present a nonlinear observer to track the excursion of insulin concentration levels measured by the 
immunosensor and the laboratory-based ELISA. Future work will focus on using the observer to study the 
integration of an insulin immunosensor to enhance the design of an augmented closed-loop.    
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Exploration of the Availability and Features 
of Diabetes Self-management Applications on 
the App Stores 
  
Abdulhakem Alhamoudi, BPharm, MSc; Vibhu Paudyal, BPharm, MSc, PhD; Zahraa Jalal, 
BPharm, MSc, PhD 
 
University of Birmingham 




This study aims to explore the availability and features of mobile applications in Google Play Store® (Android™), 
for the self-management of type 1 and type 2 diabetes in adults in English and Arabic languages. It also aims to 
compare these features with AADE7 Self-Care Behaviors®.  
  
Method: 
A web-based search performed through the Google Play Store® (Android™). The search was conducted in July 
2020 to identify applications that are specifically designed for the self-management of diabetes in the English and 
Arabic languages for type 1 and type 2 diabetes. Each application that meets the inclusion criteria has been 
downloaded, and its features explored and compared to recommended AADE7 Self-Care Behaviors®.   
  
Result: 
There were N=402 application results from the search. Of those, N=45 apps met the inclusion criteria and N=357 
did not and were excluded. Included applications, N=43 apps in English and N=2 in Arabic and support a range of 
Self-Care Behaviors: 53% Healthy Eating, 42% Being Active, 96% Monitoring, 49% Taking Medication, 11% 




The available applications are limited to supporting only some self-management tasks. Patients are required to 
install different tools for the self-management of their diabetes but not all tools are available to perform all of the 
self-diabetes management tasks. Future development should aim to develop a comprehensive evidence-based 
application to support all areas of Self-Care Behaviors.   
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The Impact of a Prolonged Lockdown and 
Use of Telemedicine on Glycemic Control in 
People with Type 1 Diabetes During the 
COVID-19 Outbreak in Saudi Arabia 
 
Sahar Alharthi, MBBS; Ebtihal Y. Alyusuf, MBBS; Abdullah M Alguwaihes, MD, MPH; Assim 
Alfadda, MD, MSc; Mohammed E. Al-Sofiani, MD, MSc 
 
Department of Internal Medicine, College of Medicine, King Saud University 




To minimize the spread of COVID-19, Saudi Arabia imposed a nationwide lockdown for over 6 weeks. We 
examined the impact of lockdown on glycemic control in individuals with type 1 diabetes (T1D), using continuous 
glucose monitoring (CGM); and assessed whether changes in glycemic control differ between those who attended a 
telemedicine visit during lockdown and those who did not. 
 
Method: 
Flash CGM data from n=101 individuals with T1D were retrospectively evaluated. Participants were categorized 
into two groups: Attended a telemedicine visit during lockdown (n=61) or did not attend (n=40). Changes in CGM 
metrics over 6 weeks of lockdown, from the last 2 weeks pre-lockdown to the last 2 weeks of the complete 
lockdown period, were examined in the two groups. 
 
Result: 
Among individuals with T1D, with the following characteristics [Medians (IQR) age: 23 (18,28) years old; diabetes 
duration: 7 (3,16) years; females: 54.46%; and insulin pump users: 28.57%], those who attended a telemedicine visit 
during lockdown had an improvement in the following CGM metrics by the end of lockdown: Average glucose 
(from 180 to 159mg/dl, p<0.01), glycemic management indicator (from 7.7 to 7.2%, p=0.03), time in range (from 
46 to 55%, p<0.01), and time above range (from 48 to 35%, p<0.01) without significant changes in time below 
range, coefficient of variability, or number of daily scans or hypoglycemic events. In contrast, there were no 




A six-week lockdown did not worsen, nor improve, glycemic control in individuals with T1D who did not attend a 
telemedicine visit. Whereas those who attended a telemedicine visit had a significant improvement in glycemic 
metrics; supporting the clinical effectiveness of telemedicine in diabetes care. 
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Predictors of Use and Improvement in 
Glycemic Indices After Initiating Continuous 
Glucose Monitoring in Real World: Data 
from Saudi Arabia 
Ebtihal Y. Alyusuf, MBBS; Sahar Alharthi, MBBS; Abdullah M Alguwaihes, MD, MPH; Anwar 
Aljammah, MBBS; Assim Alfadda, MD, MSc; Mohammed E. Al-Sofiani, MD, MSc 
Division of Endocrinology, Department of Internal Medicine, College of Medicine, King Saud University 
Riyadh, Riyadh, Saudi Arabia 
ealyusuf82@gmail.com 
Objective: 
To identify predictors of use and benefit from continuous glucose monitoring (CGM) in people with type 1 diabetes 
(T1D).  
Method: 
Changes in glycemic indices, weight, lipid parameter, and albumin:creatinine ratio (ACR) after using intermittently-
scanned CGMs for one year were examined in 116 individuals. Participants were categorized based on frequency of 
sensor scanning at month 6 into: Frequent scanners (≥10 CGM scans/day) and infrequent scanners (<10 scans/day). 
Adjusted regression models examined the association of potential predictors with improvement to time in range 
(TIR), time below range (TBR), and frequency of sensor scanning at month 6. 
Result: 
Average sensor glucose, TIR, TBR, time above range (TAR), and glycemic management index (GMI) have all 
improved significantly from baseline to month twelve (176.5 to 164 mg/dl, 43 to 50.5%, 7 to 5.5%, 48.5 to 39%, 7.8 
to 7.3%; respectively, all p<0.05) without significant changes in average scans/day, weight, lipid, or ACR (all 
p>0.05). Frequent scanners had an improvement in TIR and TAR at both month 6 and 12; whereas infrequent 
scanners only had a comparable improvement at month 12. Individuals with baseline TIR<50% had a significant 
improvement in TIR and TAR; whereas those with baseline TIR ≥50% had an improvement in TBR only. Baseline 
TIR <50% and frequency of scans were predictive of improvement in TIR at month 6 (OR: 4.84, p<0.01 and 1.05, 
p=0.04; respectively); whereas baseline TBR was the only predictor of improvement in TBR (OR:1.24, p<0.01). 
Being a woman, higher number of scans/day in the first 2 weeks, and having lower A1C at baseline were predictive 
of being a frequent scanner at month 6 (OR: 2.81, p=0.04; 1.12, p<0.01; and 0.73, p<0.01; respectively). 
Conclusion: 
Use of CGM improves glycemic control in individuals with T1D; and success can be predicted by frequency of 
sensor scanning at 6 months and baseline TIR. 
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Deteriorating Glucose Control in Patients 
with Diabetes (PWD) after Disengagement 
from A Mobile Health (mHealth) App  
  
Sarine Babikian, PhD; Vikram Singh, M Eng; Tong Sheng, PhD; Mark Clements, MD, PhD  
 
Glooko, Inc. 




Connected diabetes devices and mobile apps can be valuable for diabetes self-management, but the usage of such 
tools can be inconsistent in the real world. Discontinued use of self-management tools can lead to deteriorating 
outcomes and increases the risk of complications. In the current study, we investigated the glycemic and behavioral 
outcomes of patients with diabetes (PWD) users of a mHealth self-management app prior to and following 




We randomly selected N=472 PWD users of a diabetes management app who uploaded their diabetes device 
(glucose meters and/or insulin pumps) data remotely and at clinic appointments. To compare glucose outcomes prior 
to and post dropout, we selected PWDs who discontinued remote in-app device uploads after a minimum of 6 weeks 
of consistent use, but who subsequently uploaded their diabetes devices at a clinic visit after dropping out.  
We compared diabetes outcomes (i.e., average blood glucose (BG), percent of readings in range, percent of readings 
in hyperglycemia range, percent readings in hypoglycemia range, and number of daily glucose checks) before and 
after dropping out using paired t-tests. 
 
Result: 
The cohort had median age=19 years (IQR 13-47), 53% female, and 70% self-reported as having type 1 diabetes.  
The average BG increased from 188mg/dL during the 2 weeks prior to dropping out to 193mg/dL at 6-8 weeks after 
dropout(p=0.004). The percent of readings in range (70-180mg/dL) decreased from 46.3% to 44.6%(p=0.03). The 
percent of readings in hyperglycemia (>180mg/dL) increased from 45% to 48%(p=0.02). The average number of 
glucose checks decreased from 4 to 3.7 daily checks over the same time period (p<0.00001). We did not observe any 
changes in percent hypoglycemia.  
 
Conclusion: 
The present analysis indicates that disengagement with a mHealth app is predictive of worsening glucose control. 
Dropout risk is inherent to novel diabetes management technologies. Whether the risk of disengaging with novel 
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Closed-Loop Insulin Delivery in Adults with 
Highly Unstable Type 1 Diabetes can 
Outperform Suspend-before-Low Insulin 
Pump Technology: A Feasibility, 16-week 
Randomized Crossover Trial 
  
Pierre-Yves Benhamou, MD; Sandrine Lablanche, MD; Anne Vambergue, MD; Maeva Doron, 
PhD; Sylvia Franc, DU, DIU; Guillaume Charpentier, MD; Erik Huneker, MS 
 
University of Grenoble Alpes Hospital (CHUGA)  




Our objective was to assess whether the Diabeloop DBLHU hybrid monohormonal closed-loop system could 




In this controlled, randomized, feasibility trial, we recruited adults with type 1 diabetes with severe glucose 
instability experiencing severe hypoglycemia with a theoretical indication for islet transplantation. After a 2-week 
run-in period, patients went through a series of N-of-1 trials including two blocks of two periods of four weeks each. 
Within each block, the sequence DBLHU/PLGS or PLGS/DBLHU was randomized. The primary outcome was the 
percentage of time spent in the 70 – 180 mg/dL glucose range measured on the third and fourth week of each 
sequence. Statistical analysis was performed on the complete set. This trial is registered with ClinicalTrials.gov, 
number NCT04042207.    
  
Result: 
N=7 patients were randomized and N=5 completed the trial as planned. Using DBLHU was associated with a 29·8% 
higher (95% CI 25·1 to 34·6, p<0·0001) percentage of time in the 70 – 180 mg/dL glucose range (73·3% (1·7) vs. 
43·5% (1·7)), and improved secondary outcomes: glucose variability, satisfaction score, and perceived frequency of 
hypoglycemia. There were no treatment-related adverse events during the study..  
  
Conclusion: 
The DBLHU system may be an effective option for the unmet medical need of unstable type 1 diabetes. Closed-loop 
should be considered ahead of islet transplantation.  
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Using Dielectric Spectroscopy in Diabetes: 
Performance of the Alertgy Non-invasive 
Continuous Glucose Monitor (ANICGM) 
 
Lauren Buehler, MD, MPH; M. Cecilia Lansang, MD, MPH 
 
Cleveland Clinic 




The Alertgy non-invasive continuous glucose monitor (ANICGM) is a novel device that does not entail skin 
puncture. This study evaluated the performance of the ANICGM compared with an FDA-approved glucose meter in 
patients with type 2 diabetes. 
 
Method:  
The ANICGM device measures changes in the electromagnetic field generated by its sensor to produce a dielectric 
spectrum.  The data contained within this spectrum are used in tandem with machine learning algorithms to estimate 
BG. Values from the ANICGM were compared to BG using the Accuchek Inform II glucometer. Fifteen patients 
completed three 120-minute sessions. Two different algorithms were used for BG prediction.  Algorithm A 
estimates were generated using a model developed with data from a prior study in addition to data from this study. 
Algorithm B estimates were produced using a model that incorporated only the present study cohort. Mean absolute 
relative difference (MARD) was calculated for each study day using both algorithms. 
 
Result:  
Across all study days, percent mean absolute relative difference (MARD%) was lower using Algorithm B compared 
to Algorithm A. For Days 2&3, MARD decreased from 34.9% to 16.5% (p<0.001).  For both algorithms, MARD 
for Days 2&3 was higher than Day 1. For Algorithm A, Day 1 MARD was 29.4% and Days 2 & 3 MARD was 
34.9% (p=0.31).  In Algorithm B, MARD increased from 7.6% on Day 1 to 16.5% for Days 2 & 3 (p<0.001). 
 
Conclusion:  
These data show a strong correlation between ANICGM and FS BG measurements. This technology shows 
promising advances towards development of a noninvasive CGM. 
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Simulating Subcutaneous Tissue Using 
Ballistic Gel and Polyurethane Film for 
Infusion Set Insertion Force Testing  
 
Leilani Camara, BS; Jasmin Kastner, PhD; Kenneth Hsu, BS, MBA 
 
Capillary Biomedical, Inc.  




Establish a tissue simulator made of ballistic gel and polyurethane (PU) rubber film as a suitable model for measuring 
infusion set insertion force into subcutaneous tissue. 
 
Method: 
Three grades of ballistic gel, Gelatins #0, #1, and #2, were assembled with a 0.015” PU rubber film surface layer. 
Gelatins #0 through #2 have a Young’s Moduli of 726 kPa, 668 kPa, and 485 kPa, respectively which simulates 
subcutaneous tissue. A 0.015” thickness PU film was added to simulate dermis. Each assembly was pierced 10 times 
with a new 27G hypodermic needle and a compression testing machine operating at 140mm/min. This process was 
repeated using pig abdomen (freshly harvested, unscalded skin) for an additional 20 insertions. The maximum 
resistance force measured per insertion was recorded and analyzed. Comparison between tissue simulator and pig 
tissue was made using a two-tailed t-test and a p-value of 0.05 for statistical significance.  
 
Result: 
The average maximum insertion force (and standard deviation) for Gelatin #0, #1, and #2 assemblies was 0.71 N 
(0.04), 0.68 N (0.08), and 0.69 N (0.05), respectively. Pig abdomen required an average maximum insertion force of 
0.48 N with a standard deviation of 0.11 N. A two tailed t-test was performed between the pig abdomen and Gelatin 




Gelatin #0 with a 0.015” PU film surface layer provided an insertion force that was less variable than Gelatins #1 
and #2, but greater than that required to pierce pig abdomen tissue. This assembly was selected as a reasonable 
tissue simulator challenge medium for use in infusion set insertion verification testing.  
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Clinical Trial Having Time-in-Ranges as 
Final Endpoints 
 
Nunzio Camerlingo, MS; M. Vettoretti, PhD; A. Facchinetti, PhD; G. Sparacino, PhD; Julia K. 
Mader, MD; P. Choudhary, MD; and S. Del Favero, PhD; on behalf of the Hypo-RESOLVE 
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Determining the optimal duration of CGM recordings to accurately assess time in different glucose ranges (TIRs) is 
crucial for the design of clinical trials evaluating overall glycemic control. Too short monitoring periods provide a 
poor estimation of TIRs, affected by weekly fluctuations, while extremely long trials result in excessive costs not 
justified by real benefits. In this work, we propose a mathematical approach to determine the minimum CGM 
duration warranting a desired level of accuracy for TIRs estimate. 
 
Method: 
Framing the problem as a random variable estimation problem, we derived a mathematical formula linking the 
number N of monitoring days with the uncertainty of TIRs estimate, expressed as standard deviation SD 
(Camerlingo et al., Sci. Rep., 2020). The formula was tested on CGM data of N=148 subjects with type 1 diabetes 
and was effective for predicting the uncertainty of time in range: 70-180 mg/dL (TIR), time below range:  <70 
mg/dL (TBR), and time above range: >180 mg/dL (TAR). 
 
Result: 
For a CGM system with 5-min sampling rate, N=30 days provide a SD of 6.31% for TIR, 12.1% for TAR, 27.2% 
for TBR, meaning that an estimated 60%, 35%, and 5% of TIR, TAR, and TBR, respectively, are associated with 
±3.78%, ±4.24%, and ±1.36% confidence intervals. Furthermore, the formula suggests 56 days to reduce the SD of 
TBR at 20% and 48 days to reach a SD of 5% for TIR. 
 
Conclusion: 
We derived and validated a mathematical formula to estimate the uncertainty of TIRs already estimated from past 
clinical trials. This formula can also be used proactively to select the minimum CGM duration granting a desired 
level of accuracy, which is particularly significant in terms of clinical relevance and cost-effectiveness. 
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ReplayBG: A Novel In-Silico Framework to 
Retrospectively Assess New Therapy 
Guidelines for Type 1 Diabetes Management 
 
Giacomo Cappon, PhD; Martina Vettoretti, PhD; Giovanni Sparacino, PhD; Simone Del Favero, 
PhD; Andrea Facchinetti, PhD 
 





Design and assessment of new therapy guidelines for type 1 diabetes (T1D) management can be greatly facilitated 
by retrospective data analysis and simulation, in particular by comparing the actually measured CGM trace with the 
glucose time-course that “would have been obtained” by adopting, in the same subject, the new therapy guideline 
under test. Predicting this time-course by straightforward modeling methodologies can require strong hypotheses 
that unavoidably narrow the domain of validity of the inferred results (Vettoretti et al. Diabetes Technol Ther, 
2016). The ReplayBG framework proposed in this work avoids this limitation. 
Method: 
First, a non-linear model of glucose-insulin dynamics is determined, using a Bayesian strategy, on retrospective 
patient data where the inputs are insulin infusions and carbohydrate intake and the output is CGM. The so-identified 
model is then used to simulate and compare i) the CGM trace obtained by “replaying” the recorded scenario and ii) 
the CGM trace obtained using the insulin/carbohydrate input proposed by the therapy treatment under evaluation. To 
demonstrate the use of ReplayBG, we retrospectively compared, in fourteen T1D patients monitored for five 
months, a recently developed insulin dosing strategy (Noaro et al., IEEE Trans Biomed Eng, 2020) against the 
standard formula for bolus computation.  
Result: 
Results show that, with a limited computational time, ReplayBG is able to reliably assess new therapy guidelines for 
T1D. The considered demonstration suggests that the insulin dosing strategy of Noaro et al. outperforms the 
standard formula in terms of glucose control indices.  
Conclusion: 
ReplayBG does not rely on possibly critical assumptions made by other methods proposed in the literature and can 
safely be used to preliminarily evaluate new therapies for T1D management before moving to clinical trials. 
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Fluid Path Stability and Infusion Set 
Occlusions Comparison 
 
  Sarnath Chattaraj, PhD; Gina Zhang, PhD; Hsi Fusselman, MS; Cheryl Chambers, BS 
  
  Medtronic Diabetes 




Preliminary findings from the development of in-vitro and in-vivo insulin infusion set (IIS) test models indicate that 
inflammatory response, macrophage number, and device wear-time were significantly impacted by preservative loss 
and levels of aggregates or particles. This study compared the impact of changes in insulin preservative, impurities 
and aggregates, in Medtronic and non-Medtronic insulin infusion pumps, during evaluation of fluid path stability 
and IIS occlusion. 
  
Method: 
Fast-acting insulins (NovologÒ and HumalogÒ) and a faster-acting insulin (FiaspÒ) were pumped under simulated-
use conditions through Quick™-set infusion sets with Paradigm™ pumps (and shaken reservoirs) or Autosoft™ 90 
infusion sets with non-Medtronic pumps (and shaken cartridges). The in-vitro insulin studies were conducted for 




The in-vitro Humalog®-pumped data showed that impurity gains and preservative losses in samples from the non-
Medtronic pump and cartridges were greater compared to those observed in Paradigm™pump and reservoir 
samples, respectively. The in-vitro NovologÒ- and FiaspÒ-pumped data showed a substantially higher 
concentration of aggregates in non-Medtronic pumped samples and caused fluid path occlusion.   
  
Conclusion: 
These data help support previous test model findings and indicate that a fluid path system (i.e., reservoir or 
cartridge, IIS and the interface connection) design that reduces preservative loss and propagation of aggregates may 
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Insulin Cost-Savings Comparison: 7-Day 
Extended Wear Infusion Set with a 
Medtronic Pump vs. 2-3 Day Wear Infusion 
Set with a Non-Medtronic Pump 
 
Sarnath Chattaraj, PhD; Marisa Fienup, MBA; Hsi Fusselman, MS; Marie Tieck, PhD 
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Most soft-cannula insulin infusion sets are labeled for either 2 days or 3 days of infusion.  The potential insulin 
savings associated with extending the duration of infusion set wear from 2-3 days to 7 days has been recently 
determined. This study compared insulin waste reduction and its cost savings (based on U.S. insulin pricing) in both 
Medtronic and non-Medtronic insulin infusion pump systems under labeled infusion set wear durations (i.e. 2 days, 
3 days and 7 days).  
  
Method:  
The discarded insulin volume in the reservoir, cartridge, insulin transfer syringe and infusion set under a current-
wear scenario of 2 to 3 days versus 7 days with different insulin pump delivery systems was modeled and tested.  A 
mix of use-cases for an infusion set/reservoir (or cartridge) with different insulin pump delivery systems (Medtronic 
and non-Medtronic) was used to compute the insulin cost savings (∼$450/insulin vial). 
  
Result:  
In comparison to non-Medtronic insulin pump users, the average annual reduction in discarded insulin volume for 
Medtronic pump users was calculated to be about 7-9 vials of insulin per year for a 7-day infusion.  The 
corresponding cost reductions per pump user as a result of insulin savings was ∼$3,150 to $4,050 per year. 
  
Conclusion:  
These data suggest that using insulin infusion sets that last for 7 days, with a Medtronic insulin infusion pump 
system, can yield substantial cost savings to patients, private health plans, and other payers (e.g., Centers for 
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Characterizing the Effect of Physical Activity 
for Blood Glucose Management in People 
with Type 1 Diabetes (T1D) 
 
Divya Choudhary, PhD; Marzia Cescon, PhD 
 
Department of Chemical Engineering, Indian Institute of Technology Delhi 




To investigate the relationships between physical activity and glucose dynamics with linear mixed effect models 
(LMEMs) in patients with T1D in various conditions. 
 
Method: 
Data collected during the DIAdvisor™ project from N=50 T1DM subjects (33M/17F, age 40±12 [yr], disease 
duration 19.4±10 [yr], BMI 24.8±2.8 [kg/m2], A1c 7.8±0.9 [%], 28 MDI and 22 CSII) during 2 visits (75-hour in-
hospital and 7-day ambulatory setting) included: interstitial glucose measurements (BGM) [1Hz] sampled with 
Abbott Freestyle™, accelerometer data [1Hz] recorded with ViVoMetrics Clinical LifeShirt™ and patients annotated 
meal intake and insulin injections.  For each period from 90 minutes before to 180 minutes after a meal, LMEMs 
were used to assess physical activity as the magnitude of the accelerometer 3D-jerk [m/s3]. Fixed effects were 
estimated from the glucose dynamics: BGM value [mg/dL] and timing [min] of base and peak, time difference [min] 
between base and peak BGM; BGM rate of increase post-meal [mg/dL-min]; insulin bolus [u], carbohydrate [g] and 
area-under-the curve [min-mg/dL]. 
 
Result: 
Median values for (in-hospital, ambulatory) visits were: jerk (1.58, 1.93) [m/s3], bgm_base (108.5, 102.5) [mg/dL], 
bgm_rate_increase (0.75, 0.57) [mg/dL-min], carbohydrate (43,40) [g], insulin_bolus (45.3, 47.55) [u], bgm_peak 
(171.5, 169) [mg/dL], t_bgbase_to_bgpeak (70, 70) [min],  AUC(3510, 3695) [min-mg/dL].  Upon LMEM 
convergence, model predictions were plotted against the true value of jerk, yielding slope and intercept of the linear 




Lower BGM increase rate and higher jerk were associated with the free-living ambulatory setting. The algorithm 
characterized the BGM curve for all meals for 500 days depicting the differences for in-hospital (less physical-
activity) and ambulatory settings (more physical-activity). LMEMs were able to predict a linear relation between 
fixed effects and the accelerometer with good accuracy. This method can potentially complement existing 
techniques to improve glucose control by accounting for physical activity. 
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Continuous Glucose Monitoring in a  
71-year-old Man with Diabetes and  
COVID-19 During an Episode of Cardiac 
Arrest, Return of Spontaneous Circulation, 
and Death 
 
Kenneth W. Chow, BS; Danielle J. Kelly, NP; Igor Kravets, MD; Marina M. Charitou, MD; Eric J. 
Morley, MD, MHA, MS; Rajarsi Gupta, MD, PhD; Joshua D. Miller, MD, MPH 
 
Stony Brook Medicine, Renaissance School of Medicine at Stony Brook University 




We assessed real-time continuous glucose monitoring (rtCGM) data in an individual with type 2 diabetes who 
presented with severe symptoms of COVID-19 and suffered a fatal cardiac arrest during hospitalization. We 
evaluated (1) the utility of using rtCGM in the critical care setting through comparison with venous and point-of-
care (POC) glucose measurements and (2) report rtCGM data during the clinical scenarios of cardiac arrest, 
resuscitation, and death. 
 
Method: 
This retrospective analysis utilized rtCGM data (Dexcom G6, Dexcom Inc., San Diego, CA) to evaluate changes in 
blood glucose levels in a 71-year-old male with COVID-19 symptoms who suffered a fatal cardiac arrest. 
 
Result: 
Blood glucose levels remained constant at 220-225 mg/dL after the first cardiac event, slowly decreased to 167 
mg/dL after return of spontaneous circulation (ROSC) was achieved, decreased to 141 mg/dL over the first 
postmortem hour and quickly declined to undetectable levels within the next 20 minutes. Over the course of CGM 




rtCGM correlated well with venous and point-of-care glucose measurements and was reliably used to manage 
diabetes in this critically ill patient. Wider adoption of rtCGM may help identify blood glucose patterns and uncover 
new insights to various comorbidities and conditions. 
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Web-based Simulation Tool for Self-
Management Support in Type 1 Diabetes 
 
Patricio Colmegna, PhD; Marc Breton, PhD 
  
Center for Diabetes Technology, University of Virginia 




To design and implement a novel, user-centric, cloud-based framework that allows people with type 1 diabetes 
(T1D) to easily explore changes to their individual insulin treatment parameters or measured behaviors. 
  
Method: 
Glucose, insulin, and meal records are automatically transmitted from the patient’s insulin pump to the Web-based 
Simulation Tool, also known as WST. Field collected data are processed, including algorithms for mealtime 
correction/detection, and then fed into a scalable, computing cluster, where the reconstruction-replay engine of WST 
is personalized. Cleaned data and adjusted model parameters are saved into the system’s database on a daily basis. 
The system is presented to users as a responsive website through which they are able to visualize their data from a 
particular date range, simulate changes to their insulin parameters and meals, and generate comparison reports. 
  
Result: 
The reconstruction-replay engine of WST was evaluated using real data (study ID: NCT02558491) and synthetic 
data from N=50 virtual subjects that included meals, exercise, insulin sensitivity variability, and sensor noise and 
calibrations. The median MARD across all experiments was below 11% for both glucose reconstruction and 
synthetic prediction under basal rate and meal bolus adjustments up to 25%. In terms of error grid analysis (EGA) 
performance, predictions fell more than 99% of time into the A- and B-zones, confirming that results are clinically 
acceptable. Usability of WST will be evaluated in a pilot clinical trial under normal living conditions at home. 
  
Conclusion: 
Bringing proven simulation technologies to patients with T1D enables unique patient-data interactions that can lead 
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A Data Management Platform for the 
Assessment of New Type 1 Diabetes 
Therapies in Clinical Trials 
 
Luca Cossu, MSc; Giacomo Cappon, PhD; Giovanni Sparacino, PhD; Andrea Facchinetti, PhD 
 
Department of Information Engineering, 




Therapy of type 1 diabetes (T1D) generates a large amount of different data (e.g.: glucose sensors, insulin pumps, 
meal info and composition, activity trackers, etc.).  Effective collection, storing and presentation of such data is 
essential during clinical trials aimed at testing new therapies. The aim of this work is to present a unified platform 
able to simultaneously guarantee: security and anonymity of data; data persistence in a structured and standardized 
format; and modularity needed to implement the new therapies under test.  
Method: 
The platform is composed by a cloud database, a mobile application, and a web interface. The platform assures the 
following key features: i) safe communication with continuous glucose monitoring sensors, ii) integration of data 
generated by common healthcare applications, iii) data privacy and structuring, and iv) real-time patient monitoring. 
The mobile application is easy-to-use, intuitive, and intended to be used by patients as their diary.  
Result: 
As a preliminary test of usability, the prototype platform has been used by a volunteer patient with T1D in a short 
session lasting seven days. The volunteer reported good user experience, that has been further improved with the 
introduction of data insertion reminders and other features to keep the patient informed about his glycemic control. 
More intensive testing of the prototype is presently under development. 
Conclusion: 
The developed platform is potentially useful for data gathering and real-time patient monitoring in clinical trials 
aimed at testing new T1D therapies.  
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Cost-Utility of an Online Education Platform 
and Diabetes Personal Health Record: 
Analysis over Ten Years  
 
Scott G Cunningham, PhD; Andrew Stoddart, MSc; Sarah H Wild, PhD; Nicholas J Conway, MD; 
Alastair M Gray, PhD; Deborah J Wake, PhD 
 
School of Medicine, University of Dundee  




My Diabetes My Way (MDMW) is Scotland’s interactive website and mobile app for people with diabetes and 
carers (currently ~50,000 registrants). It contains multimedia resources for diabetes education and offers access to 
electronic personal health records. This study aims to assess the cost-utility of MDMW compared to routine diabetes 
care in people with type 2 diabetes who do not use insulin. 
 
Method:  
Analysis used the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model2. Clinical parameters of 
MDMW users (n=2,576) were compared with a matched cohort of individuals receiving routine care alone 
(n=11,628). Matching criteria: age, duration of diabetes, sex, and socio-economic status. Impact on life expectancy, 
quality-adjusted life years (QALY), and costs of treatment and complications were simulated over ten years. 
 
Result:  
MDMW cohort: 1670 (64.8%) men; average age 64.3 years; duration of diabetes 5.5 years. Females: average age 
61.6; duration 4.7 years. The cumulative mean QALY (95% CI) gain: 0.054 (0.044; 0.062) years. Mean difference 
in cost: -£118.72 (-£150.16; -£54.16) over ten years. Operating costs of MDMW at the time of analysis were 
approximately £34.20/registered user/decade, equivalent to a return on investment of well over 3:1. 
 
Conclusion:  
MDMW is ‘dominant’ over usual care (cost-saving and life improving) in supporting self-management in people 
with type 2 diabetes not treated with insulin. Wider use may result in significant cost savings through delay or 
reduction of long-term complications and increased life expectancy in Scotland and other countries. MDMW may be 
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How to Assure Insulin Quality on a 
Molecular Level by Novel Analytical 
Methods 
 
Sven Delbeck, MSc; Yannick Dederichs, BSc; David Nicklaus, BSc; Sandra Stoppelkamp, PhD; H. 
Michael Heise, PhD 
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Human insulins and their analogs can undergo different degradation processes on a molecular level when exposed to 
stress conditions, such as temperatures or shear strain, deviating from recommended manufacturer’s storage 
recommendations. These molecular processes lead to a conformational reorganization of the insulin molecules, 




Infrared spectroscopy offers a reliable approach for quantitative and qualitative insulin monitoring without the 
application of the sophisticated HPLC reference method, as stated in international pharmacopoeias. A human 
monocytes cell-based method for the determination of biological potency, using microdialysis and infrared 
spectrometry, has been tested using a USP insulin standard. Reference measurements for total insulin quantification 




Changes in the molecular structure of short-and long-acting insulins were observed after several weeks when stored 
at 37°C. When stored at ambient temperatures or just above 0°C, no significant changes have been found for 
formulated insulins, but for samples purified by ultrafiltration. An analysis of the insulin`s secondary structure 
reveals early molecular conformational changes as identified by IR-spectroscopy of dry-film samples. Agglomerates 
were detected by using a novel HPLC protocol and comparative IR measurements confirming extensive misfolding. 
Biological potency measurements were carried out using the cellular glucose metabolization rates, correlating with 
insulin concentrations in the growth medium.  
  
Conclusion: 
IR-spectroscopy offer a fast and reliable method for quality assurance and quantification of commercial insulins and 
could replace the current pharmacopeial methods. In combination with a cell-based biological potency assay, this 
approach could also meet the USP requirements. 
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Evaluation of Follow-up Rates in a Large 
Teleretinal Screening Program 
  
Sarah N. DeVaro, BA; Anjali Om, BA; Timothy L. Arleo, BS; Omar I. Ali, BS; Stacie Schmidt, 
MD; Yousuf M. Khalifa, MD 
  
Emory University School of Medicine 




Although sequelae of uncontrolled diabetes mellitus are routinely communicated to patients at office visits, patients 
seen via telehealth are often lost to follow-up. We performed a retrospective cohort study to determine follow-up 
rates of patients enrolled in the Grady Hospital’s Diabetic Teleretina screening program.  
Method: 
From 1/18/2018 to 9/28/2018, 6,876 diabetic patients in the Grady Healthcare System were screened for 
ophthalmologic complications via one of thirteen Teleretina cameras in the Atlanta area. Pathology results were 
referred to the Grady Eye Clinic (GEC) for evaluation. The study’s cohort consisted of patients found to have 
proliferative diabetic retinopathy (PDR) and/or diabetic macular edema (DME). Follow-up was determined 
successful if a patient scheduled and showed up to GEC following the screening result. The number of phone calls 
made by the staff to each patient to schedule appointments was recorded. Initial recommendations provided to the 
patient at the first GEC appointment were used to track patient adherence to treatment plan.  
Result: 
N=269 patients were diagnosed with PDR and/or DME via Teleretina screening. Eyes were tracked individually. 
369 of  538 eyes made it to the first GEC visit, yielding a 68.9% follow-up rate. Over half (55%) of patients 
completed initial treatment recommendations. Average time from screening to first visit was 46.1 days. Almost 
three-fourths (72.7%) of patients showed up to GEC after receiving one scheduling phone call from staff, 54.7% 
after two calls, and 44.4% after three calls. 
Conclusion: 
The Grady Teleretina Screening Program successfully set up appointments within two months for nearly 70% of 
patients with PDR and/or DME. Over half (55%) completed initial treatment recommendations. However, a 
significant portion of patients remained lost to follow-up. Additional attempts to contact patients displayed 
diminishing returns. Further studies should investigate barriers to care following telehealth screening.   
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Pandemic 
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Behavioral changes associated with the COVID-19 pandemic may influence diabetes management decisions and 
glycemic control among users of continuous glucose monitoring (CGM) systems. We sought to examine the effects 
of the pandemic on CGM metrics that typically differ between weekends and weekdays. 
 
Method: 
Data were from a convenience sample of 4,703 users of the G6 CGM System (Dexcom, Inc., San Diego, CA) with 
postal codes in either New York City (New York), Los Angeles County (California), or Cook County (Illinois) and 
were required to have uploaded at least 70% of possible glucose concentration values between 01-01-2020 and 06-
20-2020. Pre-pandemic and late-intra-pandemic intervals were defined as 01-01-2020 to 03-01-2020 and 04-20-
2020 to 06-20-2020, respectively. Weekends were Saturdays and Sundays; other days were weekdays. Time in 
range (TIR) was defined as the percentage of glucose values in the 70-180 mg/dL range. Glycemic variability was 
calculated as coefficient of variability (CV). Paired t-tests were used to compare the changes in daily % TIR and 
CV, before and during the pandemic.  
 
Result: 
Before the pandemic, weekends were characterized by significantly lower mean±SD TIR values than weekdays 
(58.3± 26.6 vs. 59.5± 26.5%, respectively, p<0.001). During the pandemic, weekend TIR improved to 61.6% and 
weekday TIR improved to 62.2%. The magnitude of the weekend/weekday TIR discrepancy decreased from 1.2 ± 
6.2% pre-pandemic to 0.6 ± 5.6% intra-pandemic, p<0.001. Before the pandemic, weekend and weekday CV's were 
29.3% and 28.7%, respectively; these fell to intra-pandemic levels of 29.0% and 28.5%.   
 
Conclusion: 
Early stages of the COVID-19 pandemic were associated with significant improvements in TIR, as well as with a 
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Individualized Linear Models  
for Glucose Prediction:  
Parametric vs. Non-Parametric Identification 
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Accurate personalized models of glucose-insulin dynamics can be extremely useful in improving methods to 
forecast glucose concentration, thus permitting more effective and proactive glucose management. Here, exploiting 
information on injected insulin, carbohydrate intake, and past glucose samples, we investigated and compared the 
performance of two different approaches for, in particular, linear black-box model identification of such models: 
parametric vs. non-parametric. 
 
Method: 
For the parametric approach, that restricts the search of the system dynamics to a finite-dimensional set of functions 
parametrized by a parameters vector, we derived individualized linear predictors using the Prediction Error Method 
(PEM), the state-of-the-art identification technique, and the most general model parametrization (Box-Jenkins). For 
the non-parametric approach, we implemented ad-hoc code solving an optimization problem in an infinite-
dimensional functional space known as reproducing kernel Hilbert space. Both approaches were used to identify a 
model for N=11 real subjects. Model performance was assessed by computing Coefficient of Determination (COD) 
at different prediction horizons (PH), and the results were compared using ANOVA. 
 
Result: 
Non-parametric models grant an improvement of COD of about 2%, 7%, 21%, and 41% for, respectively, a PH = 
30, 60, 90, and 120 min. The paired-sample t-test confirms that the prediction accuracy is significantly different for 




The use of a non-parametric approach grants statistically significant improvement to prediction accuracy with 
respect to the state-of-art parametric approach. Notably, the so-identified personalized models can also be used as 
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We aim to: (1) test the usability and acceptability of a diabetes self-management and technology education 
simulation platform, and (2) develop a monitoring function by which diabetes device data is used to assess needs 
and personalize education.  
  
Method: 
Thirteen rural adult insulin pump users with T1D participated in a mixed methods usability study. Participants 
navigated 3 simulations (i.e. site occlusion, hypoglycemia, exercise) using a virtual insulin pump built into the web-
based platform. Testing was initially done in clinic but converted to virtual in response to COVID-19 restrictions. 
Diabetes devices were downloaded to evaluate associations between platform performance and personal device 
data. A Synthetic Minority Oversampling Technique was used to fit predictive models and decision trees were used 
to visualize patterns leading to good or poor simulation performance. Semi-structured interviews examined recurring 
themes reflecting usability and acceptability.  
 
Result: 
Participants were 28-70 (mean 51.3) years old, 77% (10/13) used automated insulin delivery devices, and 92.3% 
(12/13) used continuous glucose monitoring. Mean Net Promoter Score of 9.5 (range 9-10) and positive sentiment 
during interviews indicated very high acceptability. Systems usability scale (mean 88.5, range 70-100) indicted a 
high degree of perceived usability. Self-monitoring blood glucose/frequency >4.4, bolus/frequency >5.4 and 
Diabetes Knowledge-2 Insulin Sub-section score >9 predicted successful site-occlusion scenario performance with 
an 80% accuracy. Round 1 modifications included glucose meter addition, playback button, algorithm adjustments, 
and avatar upgrades to address platform confusion and functionality issues. Modifications suggested from round 2 
included: virtual CGM, additional content library, personalized content, and brand specific devices.   
 
Conclusion: 
Virtual simulation platforms show significant potential to increase access and frequency of self-management and 
technology education. Additional study is needed to determine sustained engagement and the benefit associated with 
simulation education technologies.   
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Previous studies demonstrated improved glucose control and less hypoglycemic events using a standardized protocol 
when transitioning from intravenous (IV) infusion to subcutaneous (SQ) insulin. A calculator was developed at 
UCSD Health to assist with insulin transition by providing SQ recommendations based on infusion requirements, 
diabetes history, and nutrition. Prior to integration with the electronic health system, this has primarily been 
available to pharmacists and trialed by few providers. The goal was to determine whether this is a safe application 
for all physicians to utilize.  
  
Method: 
A single-center, retrospective assessment was performed of hospitalized patients between October 2019-April 2020 
in whom insulin transition was ordered using the transition calculator. First, patient charts were reviewed for the 
accuracy of the physician-inputted data.  Then, the total daily dose (TDD) of SQ insulin was compared between 
calculator recommendation versus ordered dose. The primary safety outcome was incidence of hypoglycemia within 
48 hours of transition. 
  
Result: 
Of n=24 patients, 8% (n=2) experienced hypoglycemia (BG <70 mg/dL).  One event was secondary to 
insulin:carbohydrate mismatch by the nurse. The other was due to high-dose steroid discontinuation following 
transition. Overall, the calculator recommendations were on the conservative side, as more patients experienced 
hyperglycemia when the TDD was within 10% of the calculator’s recommendations (80%) compared to TDD 
greater than 10% of the recommendations (40%). The exception to this was a patient on high-dose steroids, which 
caused artificially elevated TDD recommendations.  
  
Conclusion: 
Excluding patients on steroids, the insulin transition calculator recommendations were conservative and responsible 
for zero hypoglycemic events. Therefore, we believe this application may be applied safely by all providers 
following education on nutrition input and limitation in the setting of steroid use.  
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Reversing Prediabetes Diagnoses with 
Sustainable Lifestyle Intervention 
 











Patients who had been diagnosed with prediabetes or type 2 diabetes were provided access to a digital health 
program and a personal health coach. The multi-disciplined health coaches included qualified and registered 
dietitians, trainers, physiotherapists and nutritionists who provided tailormade guidance, support and empathy, 
through video and text to help patients tackle or prevent type 2 diabetes. Patients could log and track multiple health 
goals including exercise, diet, mood, medicine, weight, blood pressure, and sugar levels, which can then be 
monitored by their personal coach. Over a 12-month program, the aim was to lower the weight of obese patients and 
reduce A1c levels for patients living with prediabetes or type 2 diabetes. 
 
Result: 
Real-world data across Liva’s population, a combination of randomized controlled trials (RCT) and observational 
studies, showed that: 
¥ 38% of people with obesity on the program had sustained a weight loss of 5% of their body weight at 12 
months.  
¥ 47% of people on the program living with prediabetes normalized their long-term blood sugar below the 
threshold for prediabetes. 
¥ 80% of people on the program living with prediabetes sustained a reduced A1c at 12 months. 
¥ Average bodyweight reduction of 6.3% after nine months among people on the program living with type 2 
diabetes, corresponding to an approximate 20% reduction in societal costs. 
  
Conclusion: 
By giving people access to a digital health coach, patients with prediabetes or type 2 diabetes are able to 
dramatically improve their health. A single health coach can supervise up to 500 patients per year, making this a 
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Maximizing IV Insulin Safety and Outcomes 
for Inpatients with COVID-19: 
eGMS Availability & Protocol Adjustments 
  
Laurel Fuqua, RN, MS; Paul Chidester, MD, FACP; Cathy Jaynes, RN, PhD 
 
Monarch Medical Technologies 




Poor inpatient glycemic management worsens outcomes for patients with COVID-19. Managing hyperglycemia 
amid challenges of bed, staffing, and PPE shortages is complicated by the hourly glucose checks required by most 
IV insulin protocols. The purpose of this study was to review the impact of a support kit provided to accommodate 
care modifications for inpatient glycemic management in the COVID-19 inpatient population.  
 
Method:    
All clients using an IV electronic glycemic management system (eGMS) received a Diabetes and COVID-19 
Support Kit with current pandemic resources and were also offered an opportunity to quickly expand the eGMS 
availability in units needed to meet surge demands. The Kit provided guidelines for changing parameter settings to 
safely achieve blood glucose levels of < 180 mg/dL while transitioning to 2-hour glucose check once patients were 
within goal range. A survey was distributed to hospital systems that deployed a component of the support package. 
 
Result:   
Thirty percent of targeted hospital systems completed eGMS unit expansions increasing availability to 3,277 more 
beds. Fifteen hospital systems returned the survey. All survey respondents had treated COVID-19 patients and were 
concerned about conserving PPE and the exposure risk associated with frequent glucose checks. Four-fifths (80%) 
of respondents felt eGMS helped them better manage COVID-19 patients with diabetes; 4 hospital systems reported 
some adjustment of parameters. Only 1 hospital system had used CGM in the previous months and only as a trial 
utilization for tracking glucose variability. 
 
Conclusion:   
Further collaboration with clients regarding the COVID-19 parameter settings adjustments is ongoing to assess the 
impact on workflow and patient outcomes. Subsequent studies of sites that made parameter changes will enhance 
support opportunities in the ongoing COVID-19 response. 
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The Extended Wear Infusion Set –  
A Design for Plastic Waste Reduction    
 
Hsi Fusselman, MS; Sarnath Chattaraj, PhD; Marisa Fienup, MBA; Owen Rooney, MBA 
 
Medtronic Diabetes 
Northridge, CA, USA 
jenny.fusselman@medtronic.com 
 
Objective:   
Most insulin pump therapies require frequent insulin infusion set changes to avoid events such as skin irritation, 
infection, occlusion, or set loss at the infusion site. This, in combination with the single-use medical device model 
that lowers the risk of infection and/or injury, can contribute to a considerable amount of plastic waste.  This study 
compared the environmental impact of the Medtronic 7-day Extended-Wear Infusion Set (EWIS) to that of current 
on-the-market serter-incorporated infusion sets.  
  
Method: 
The average amount (kg/year) of disposed plastic (i.e., the cannula, hub, tubing, cap, disconnect cover and 
disposable serter) at the end of the labeled product service life of six serter-incorporated infusion sets with different 
tubing lengths (i.e., the MiniMed™ Mio™ and Tandem Autosoft™ 90 [24 to 25 g/each], Mio™ 30 and Tandem 




Plastic waste was reduced by an average of 1.5 - 1.9 kg annually by using the EWIS in place of Mio™ and Autosoft™  
infusion sets. In aggregate, the EWIS is estimated to reduce overall plastic waste by over 496 metric tons/year. 
 
Conclusion: 
The use of a 7-day EWIS substantially reduces plastic waste compared to a 3-day wear serter-incorporated infusion 
set, resulting in a more environmentally sustainable option for infusion sets. 
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Use of a Mobile Platform to Improve 
Diabetes Management in Adolescent Type 1 
Diabetes Patients: A Pilot Study 
 
Laura Gandrud, MD; Krista Mullen, BS; Zainab Adelekan, BS; Michele Borgstrom, RN, CDE; 
David Watson, PhD; Timothy L. Barnes, PhD, MPH  
 
Children’s Minnesota Research Institute and McNeely Pediatric Diabetes Center, Children’s Minnesota 




POPS!one is a mobile platform designed to simplify diabetes self-management.  The platform integrates a self-
contained glucose meter and test modules with an interactive mobile application with results automatically 
accessible for remote clinical review.  Preliminary testing validated accuracy of blood glucose (BG) measurements 
and a less painful lancet experience compared to traditional devices.  We examined the impact of sustained use on 
A1c, test frequency, and average BG. 
 
Method: 
Fifty-one adolescent injection-users with T1D were enrolled into a prospective, single arm, clinical trial and used 
POPS!one for 6 months with follow-up at routine quarterly visits.  Differences between A1c, average BG, and test 
frequency at baseline and 6 months were compared using generalized mixed effects regression.  
 
Result: 
Overall, N=20 patients completed the study, with N=31 patients not completing the study (withdrawal, failure to 
meet minimum test requirements, lost to follow up).  Among the completers, 65% were male and 90% 
White/Caucasian; average age was 15.8±2.9 years, with a mean T1D duration of 5.6±3.6 years.  Average A1c 
improved significantly from 8.97±0.65% at baseline to 8.50±0.98% at 6 months (p-value=0.0052).  Of the 
completers, there were no demographic or baseline clinical data that predicted improvement in A1c.  Given the 
attrition rate,  completers and non-completer populations were compared;  at baseline, completers had lower A1c 
(8.97 +/-0.65 v 9.49 +/-0.8, p-value = 0.0128) and lower average BG (204 +/- 44 v 237 +/-47, p-value = 0.0178) 




Our findings suggest that sustained use of POPS!one supports diabetes management with significant improvement in 
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Highly Miniaturized, Low Power CMOS 
ASIC for Long-Term, Needle-Implantable 
CGMs  
 
Raja Hari Gudlavalleti, MS; Allen Legassey, MS; Pik-Yiu Chan, PhD; Joon-Sung Kim, PhD;  
Diane J. Burgess, PhD; Fotios Papadimitrakopoulos, PhD; and Faquir Jain, PhD. 
 
University of Connecticut 




This objective of this work is to develop a highly miniaturized, needle implantable, biosensing platform for a 
continuously glucose monitoring (CGM) system. The biosensing platform for the CGM system comprises glucose 
sensing elements with custom developed application specific integrated circuit (ASIC) chip, fabricated using 65 nm 
CMOS technology geared to reduce both size of the implant and its power requirements. The reduced power of the 
chip on the implant system provides improved coupling with solar power together with longer battery life for the 
external proximity communicating device.   
 
Method: 
The electrochemical glucose biosensors under development at Biorasis/UConn were integrated with a 65 nm CMOS 
signal processing chip. This chip interacts with the glucose sensing electrodes and transmits digital pulses optically 




The device platform demonstrated a linear response (R2=99.5) to glucose challenges with a sensitivity of 1278 
Hz/mM. The ASIC CMOS chip has a small physical footprint (0.45 mm × 1.2 mm). This chip, integrated with 
biosensor platform and opto-electronic components, had an overall power consumption ~60 µW. 
 
Conclusion: 
The miniature footprint of the biosensor platform, together with its low power consumption, renders this a versatile 
platform for minimally-invasive, fully-implantable, real-time CGM. This platform is small enough to be inserted in 
the subcutaneous tissue through a 14-gauge needle. This system is intended to improve the quality of life for patients 
with type 1 and type 2 diabetes. The development of the 65 nm CMOS chip was supported by US Army and clinical 




DTM 2020 Abstracts A427DTM 2020 Abstracts  A31 
 
Performance of the GLUCOCARD Shine 
Blood Glucose Monitoring Systems 
Throughout Shelf-Life 
 
Ryan S. Hanson, BS; Patricia Gill, BA, MLT 
 
Arkray USA 




Blood Glucose Monitoring Systems (BGMS) need to provide accurate results throughout their product life cycle. 
ARKRAY employs rigorous quality testing programs for the release of new test strip lots and evaluates a sampling 
of lots over the entire product life cycle, including expiration. Currently, FDA 2016 over-the-counter accuracy 
criteria is the most stringent for self-monitoring blood glucose systems. The accuracy boundaries for this standard 
require 95% of BGMS results to be within ±15% of the reference analyzer and 99% of BGMS results to be within 
±20% of the reference analyzer. 
 
Method: 
Seven lots of GLUCOCARD Shine test strips are currently being evaluated or have been evaluated at the ARKRAY 
laboratory in our on-site IRB approved clinical study. Four lots are in the process of being tested while three lots 
have been tested through the product shelf-life (i.e., 24 months) and post-expiration (up to 32 months). Our on-site 
clinical testing includes capillary blood sampled from the fingertip of people with diabetes (n=30 at each time point) 
by laboratory professionals for a total n=929 samples. Reference values were obtained using the YSI Model 2300 
Analyzer. Data were analyzed against FDA 2016 over-the-counter accuracy standard. Average bias throughout 
shelf-life and 95% Confidence Intervals (CI) were calculated. 
 
Result: 
A total of 96.9% (900/929) of results were within ±15% of reference and 99.1% (921/929) of results were within 
±20% of reference. Average bias within shelf-life, throughout shelf-life, and post-expiration for all lots combined 
was 1.13% [95% CI of 0.72% to 1.53%].   
 
Conclusion: 
Data collected on the GLUCOCARD Shine BGMS platform performed within the accuracy boundaries of the 2016 
FDA over-the-counter accuracy standard and demonstrated consistent performance throughout its product life cycle. 
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Radiometer ABL90 Flex Blood Gas Analyzer 
versus YSI 2300 Stat Plus Method 
Comparison 
 
Ryan S. Hanson, BS; Patricia Gill, BA, MLT 
 
Arkray USA 




Blood gas analyzers have the potential to replace the YSI 2300 Stat Plus as a glucose reference analyzer following 
discontinuation of the device in 2021. Testing documented here assessed the glucose performance of the Radiometer 
ABL90 Flex against the YSI 2300 on samples collected from people with and without diabetes. Method comparison 
analyses were carried out to determine the suitability of the ABL90 Flex as a glucose reference analyzer. 
 
Method: 
Three ABL90 sensor lots were tested alongside the YSI 2300 in Arkray on-site clinical and in-house capillary 
testing. Arkray on-site clinicals test capillary whole blood sampled from the fingertip of people with diabetes by 
laboratory professionals (n=174; 29 donors, tested in duplicate, at 3 time points). In-house capillary testing consisted 
of capillary whole blood sampled from the fingertip of people without diabetes by laboratory professionals (n=60; 
15 donors, tested in duplicate, fasting and postprandial states). ABL90 testing utilized capillary whole blood, and 
YSI 2300 testing utilized capillary plasma. One ABL90 sensor cassette was excluded from dataset due to solution 
pack issues.  Data were analyzed using difference plots [median bias and quantile limits of agreement (LoA)] and 
weighted Deming linear regression with all associated statistics reported. 
 
Result: 
No statistically significant differences were found between ABL90 and YSI 2300 glucose data. Weighted Deming 
linear regression equation: [ABL90] = 0.8676 + 0.9902[YSI 2300]. Intercept: 95% CI: -2.451 to 4.186; p-value 
0.6056. Slope: 95% CI: 0.9662 to 1.014; p-value 0.4218. Relative difference plot median bias of -0.64% [95% CI: -
0.976% to 0.000%] with LoA -4.81% [95% CI:-5.515% to -4.367%]  to 5.11% [95% CI: 3.774% to 20.408%] with 
95.7% of results within LoA.     
 
Conclusion: 
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The Effect of a Digital Therapeutic Platform 
on Glycemic Control in Adults above Age 65 
with Type 2 Diabetes 
 







A commonly held belief is that older adults may not be technically savvy enough to benefit from digital 
therapeutics. The present study examines whether the Dario digital therapeutic can contribute to better diabetes 
management in adults above age 65. Dario digital therapeutic solution consists of a mobile application, coaching, 
and glucometer integration. 
  
Method: 
A population of 12-month Dario active users with type 2 diabetes, non-insulin treated, whose first-month blood 
glucose average was greater than180 mg/dl, was evaluated. Clinical outcomes included average blood glucose, ratio 
of very high readings (>250 mg/dL) per total measurements and the percentage of population that reduced their 
average blood glucose below 169 mg/dL (equivalent to A1c 7.5% the glycemic goal for older adults according to 
American Diabetes Association). Users were stratified into two groups: one age group ≥65 years and second age 
group <65 years.  
  
Result: 
Users in age group ≥65 (N=298) improved their average blood glucose at six months by 13% (187±38 vs. 
214±50mg/dL) and sustained outcomes for 12 months (12 month average blood glucose =184±37mg/dL). This 
observation was comparable in age group <65 at 12 months (N=642) (195±36 vs. 221±52mg/dL). High readings 
ratio (>250 mg/dL) was reduced in age group ≥65 by 38.1% at six months and by 41.5% at 12 months. The ratio of 
high readings in age group ≥65 was significantly lower than in the age group <65 at 12 months (13.7% vs. 20.6%). 
47% of users in age group ≥65 (140 out of 298) reduced their average blood glucose below169mg/dL at 12 months.  
  
Conclusion: 
Older adults using a digital therapeutic platform, have the potential to promote behavioral modification and enhance 
adherence to diabetes management, demonstrating better glycemic control. 
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Glycemic Response to Athletic Competition 
Stress   
 
Nicole Hobbs, BS; Rachel Brandt, BS; Sadaf Maghsoudipour; Mert Sevil, PhD; Ali Cinar, PhD 
 
Illinois Institute of Technology, Department of Biomedical Engineering  




The objective is to understand the glycemic impact of athletic competition stress and to identify factors that make an 
individual more likely to observe this phenomenon.  
 
Method: 
Recreational athletes with type 1 diabetes were recruited for a total of N=7 runners (5M/2F) in 9 races. Participants 
completed in athletic competition and in a training run at race-pace for a shorter duration and without the stress of 




The area under the CGM curve (AUC-CGM) for training increased with increasing anxiety-proneness measured by 
the State Trait Anxiety Inventory, STAI–T (r=0.84, p=0.004). The difference in AUC-CGM between these sessions 
decreased with increasing STAI–T scores with lower STAI-T individuals observing a larger difference between 
competition than training (r=-0.73, p=0.03). In 6/ 9 sessions, we observed a larger AUC-CGM for the race compared 
to training and those sessions corresponded with lower STAI-T score individuals. The higher STAI-T individuals 
frequently experienced hyperglycemia in both sessions. The time in each glycemic range was generally less 
favorable during the race with more time spent below 70mg/dL and above 250mg/dL. The participants with longer 
duration of diabetes often took more insulin with their carbohydrates on race day than on the training day while the 
reverse occurred in newly diagnosed athletes (r=-0.69, p=0.04). 
 
Conclusion: 
Competition stress may lead to an elevated glucose trend compared to a training exercise at the same intensity in less 
anxiety-prone individuals -  those less likely to be stressed in non-competition events. With increasing duration of 
diabetes, experienced athletes  might anticipate this phenomenon and, therefore, take preventative measures such as 
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Evaluation of Twitter as an Educational Tool 
for Diabetes Self-Management Using the 
AADE7™ Framework  
 
Nishant R. Jain, MS, MHA; Suzanne Boren, MHA, PhD 
 
University of Missouri 




Using social network analysis to categorize diabetes self-management (DSM) information on Twitter against seven 
categories from AADE7™ guidelines 
 
Method:  
The study design included retrieving tweets and social network diagrams using NodeXL. Twitter data were collected 
over a period of 14 days in March 2020.  The word diabetes was added to each of the AADE7 self-care behavior 
terms to be used as a composite search term (For example, diabetes + monitoring = diabetes monitoring).  We 
extracted the tweets and the type of network. Parameters such as vertices (v), edges (e), top influencers, URLs, kinds 
of users, and top keywords were compared among the seven categories. 
 
Result:  
A social network analysis using the seven AADE7TM categories revealed that all seven exhibited a broadcast type of 
social network. There were stark differences in frequency of AADE7TM term usage, types of influencers, and themes 
that emerged. “Diabetes monitoring” was the most common self-care behavior mentioned on Twitter (vertices=312, 
edges=471), followed by “diabetes healthy eating” (vertices=194, edges=188). Further, “healthy coping” (vertices 6, 
edges= 6), was the least common self-care behavior mentioned on Twitter followed by “Problem Solving” (vertices 
13, edges= 15).  
  
Conclusion: 
A broadcast type network indicates powerful agenda setters and conversation starters on Twitter for all seven 
AADE7TM categories. Specifically, “Diabetes Monitoring” included keywords such as telemedicine, URLs such as 
eBay, and involved influencers such as the President of the United States and a physician who had been in a legal 
and social media controversy with him. Further, this study indicates that exact terms such as “healthy coping” and 
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Predicting Blood Glucose Levels Using CNN-
LSTM Neural Networks 
 
Mehrad Jaloli, MSc; Marzia Cescon, PhD 
 
University of Houston 




In this work, a convolution neural network–long short-term memory (CNN-LSTM) architecture was exploited to 
predict the blood glucose (BG) levels for a 30-60-90 minutes prediction horizon (PH) based on a multivariate 
physiological dataset of type 1 diabetes (T1D) patients.  
 
Method: 
Under the aegis of the research project DIAdvisorTM, data were collected from N=59 T1D patients (37 Male/22 
Female, mean age: 43.4±11.7 [yr], disease duration 18.8+10.7 [yr], BMI 23.9±2.4 [kg/m2], A1c 7.8±1.6 [%], 27 
MDI and 32 CSII) participating in a 3-days in-hospital study. Patients were served standardized meals for breakfast, 
lunch and dinner (carbohydrate content: 42, 70, 70 [g], respectively) and decided insulin needs based on their 
personal blood glucose meter. The dataset included: interstitial glucose [mg/dL] measured by Abbott FreestyleTM, 
insulin intake [u] for basal, bolus and corrections, and meal nutrient content [g] for carbohydrate, protein and 
lipids.  After preprocessing, the dataset was divided into 80% for train/validation and 20% for testing, respectively 
without randomization, to ensure that no information from the test patients was included in the training process. 
Then train/validation set was randomly divided into 80%-20%. A CNN-LSTM network was trained for 200 epochs 
with batch size of 128 (1s and 7ms per epoch). 
 
Result: 
Evaluating the model performance in predicting the CGM for patients in the testing set resulted in mean absolute 
error (MAE) of 6.49, 12.9, 27.52 [mg/dL], and root mean square error (RMSE) of 9.9, 19.9, 32.1 [mg/dL] for 30, 60, 
and 90 minutes PH, respectively, which, to our knowledge, are among the best performing for 
specifically 90 minutes PH. 
 
Conclusion: 
For people with T1D, accurate forecasting of BG levels would effectively avoid hyperglycemia and 
hypoglycemia. The proposed approach, based on a CNN-LSTM model, reliably predicts retrospective clinical blood 
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Painless Insulin Delivery Through the Skin 
based on Sonophoresis (Ultrasound) 
 
Eduardo W. Jørgensen, BS;  Carlos K. Jørgensen, BS; Rafael Danilo García, BS; Alejandro Ruíz, 
BS 
 
University Autónoma of Madrid 




There is a need to develop new ways of administering insulin that can increase the patient’s quality of life and 
adherence without decreasing the efficacy of the therapy. Medicsen is testing an insulin administrator based on 
sonophoresis to ensure the painless and effective transdermal delivery of insulin.  
  
Method:  
Sonophoresis and transdermal insulin delivery was tested both in vitro and in vivo over two years to prove safety and 
efficacy. (Permeability studies were used to prove efficacy as well as safety studies for insulin and the skin). 
  
Result:  
All tests produced positive results indicating the lack of damage to both the insulin molecule, which maintains its 
biological function and stability as seen in vivo and in HPLC studies or in the circular dichroism spectra obtained 
from the Lantus Insulin solution treated with the technology, finding no variability among the samples evaluated (n 
= 7), reaching the characteristic minimum at 219 nm (sd +/- 8.31) in both experimental and control groups.  Skin 
tests of sonophoresis showed no significant damage as demonstrated by electronic microscopy evaluation of the skin 
or by ELISA in which changes in the expression and concentration of relevant skin cellular compounds such as TNF 
α and IL-2. Lastly, the technology proved to be effective in the delivery of insulin molecules through the skin in a 
non-invasive way, as observed in a Franz Diffusion Cell system, and by the reduction of blood glucose in vivo. 
  
Conclusion:  
All evidence collected during in vitro and in vivo studies shows promising results, indicating that the technology 
developed by Medicsen is safe and effective. As a result, human trials will be performed in order to fully 
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Persistent Hyperglycemia in Extremely Low 
Birth Weight Premature Infants 
 
Jennifer Knopp, PhD; Adrienne Lynn, MBChB; J. Geoffrey Chase, PhD 
 
University of Canterbury 




Hyperglycemia, high blood glucose (BG), is very common in very/extremely premature infants due to stress and 
metabolic prematurity, and is associated with increased mortality and morbidity. STAR-GRYPHON is a model-
based decision support system for insulin dosing in the neonatal intensive care unit since 2013 in Christchurch. This 
study examines model-based glycemic control outcomes against a retrospective cohort to assess trends in delivery, 
quality of control, and metabolic physiological response.  
 
Method:  
Retrospective analysis of glycemic control outcomes from STAR-GRYPHON (January 2013-2019, n=59 episodes, 
4929 hours) was compared to a 2008 cohort (n=25, 2946 hours) treated with a sliding-scale insulin protocol. STAR-
GRYPHON control was compared yearly to discern trends in delivery and physiology. Glycemic control outcomes 
were assessed by percentage (hourly-resampled) BG >180mg/dL, percentage BG in 72-144mg/dL range, and 
percentage BG less than 72 mg/dL. 
 
Result:  
STAR-GRYPHON had lower BG (Median [IQR] BG 130 [112-153]mg/dL vs. 142 [119-166]mg/dL), greater time 
in target range (66% vs. 52%), less hyperglycemia (9.6% vs. 16.4% BG >180mg/dL), and lower incidence of mild 
hypoglycemia (0.46% vs. 2.1% BG<72mg/dL) compared to retrospective care.  
Time in range was highest in 2013 (76.6%), decreasing over 5 years due to persistent early hyperglycemia in some 
patients. Persistently hyperglycemic infants received insulin doses comparable to the adult saturation range (0.09- 
0.2 U/kg/hr) - indicating an upper limit of the insulin effect, and had lower weight and gestational age. 
 
Conclusion:  
Infants under STAR-GRYPHON are increasingly more insulin resistant over a 6-year study period. Insulin 
saturation and subsequent hyperglycemia, as evidenced in the data and trends, limits overall control performance, 
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Measuring Metabolic Impact and Recovery 
in Endurance Athletes Using CGM 
  
Diana Kulawiec; Tony Zhou, PhD; Jennifer L. Knopp, PhD; J. Geoffrey Chase, PhD 
  
Department of Mechanical Engineering, University of Canterbury 




Exhaustive endurance events incite significant metabolic impact. One major objective in the sporting industry is to 
accurately monitor athlete recovery to optimize training efforts and event performance. Continuous glucose 
monitors (CGMs) provide frequent, minimally invasive, blood glucose (BG) measurements, which can potentially 
capture the metabolic impact and trajectory of a major endurance exercise event and subsequent recovery. This 
study tests this hypothesis using data from sub-elite athletes. 
  
Method: 
Ten (N=10) sub-elite athletes were recruited and fitted with CGM devices. BG was monitored for 4-6 days. All 
nutrition and exercise inputs were recorded. Athletes performed an endurance exercise test to exhaustion after 1-2 
days of monitoring after a prior rest day. Validated State and Substate pattern analyses quantified glycemic levels 
and variability before and after the exercise test, overnight basal glucose behaviors, and BG response to 
carbohydrate intake.     
  
Result: 
Overall glycemic variability increased from the 80th percentile on the day of the test and returned to baseline (day 
prior) levels the day after the test. Overnight BG remained elevated up to 3-4 days post-test with an average increase 
of 16% compared to the night before the test. Metabolic variability in response to carbohydrate intake was increased 
from the 60th percentile upwards on the day of the test, returning to baseline pre-test levels the day after. These 
results capture the metabolic impact of the test and subsequent recovery. 
  
Conclusion: 
The initial hyperglycemic post-test period and lasting metabolic impact of an endurance test to exhaustion are 
quantifiable in commercially available CGM devices. These results encourage further investigation into using 
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Unannounced Meal Management within the 
DBLG1 System 
 








The objective is to implement an Unannounced Meal Management (UMM) feature that would detect and manage 
any unexpected sudden increase of blood glucose in a safe and efficient way. 
 
Method: 
The method involves three stages: 1) a meal estimation, 2) a detection module and 3) a computation of the insulin 
required to offset the estimated meal. The controller was evaluated in silico with and without the activation of the 
UMM feature, using a simulator based on the Hovorka model involving N=120 virtual patients. Various meal 
scenarios were considered with different levels of meal announcement ranging from 0% to 100% meal 




The simulation results showed a time in range [70-180 mg/dL (TIR)] improvement of 5% without increasing the 
hypoglycemia rate (<70 mg/dL) when the UMM  feature is active in a full unannounced meal (FUM) scenario. 
Results in a full announced meal (FAM) scenario also reveal that the UMM feature did not increase hypoglycemic 
risk significantly while leading to a slight TIR improvement (~0.5%) that can be imputed to unexpected glycemic 
excursions not related to meal intake, yet covered by the UMM module. These figures also show that the UMM 
controller approached, in the FUM scenario, the performances obtained in the FAM scenario with the reference 
controller: the TIR is only <5% lower (56.51% with UMM in FUM vs. 61.94% with reference in FAM). 
 
Conclusion: 
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The Smartphone as a Complete Device for 
Diabetic Telehealth in COVID19 
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The objective is to find smartphone features and free apps to provide care to our diabetic patients in the COVID-19 
and shelter in place restrictions. 
 
Method: 
We assessed the most popular downloaded communication apps in Droid and iOS app stores and pertinent 
smartphone features for diagnosis. 
 
Result: 
In the first half of 2020, Apple and Google app downloads have increased by 22.8% and 27.3%, respectively 
Communication: Top 10 free Android apps: 1) Skype, 2) Zoom, 3) RingCentral, 4)V-see, 5) Vidyo 6) Telehealth by 
Simple Practice 7) Medici: Video chat 8) eVisit Telehealth 9) Jiyyo: A TeleHealth Platform for Doctors 10) 
DocsInc. Downloads range from 1 billion for Skype to 1000 downloads for DocsInc. Top 4 free iOS apps: 1) Skype, 
2) Zoom, 3) Telehealth by Simple Practice 4) Medici. Built-ins: Facetime (iOS), Google Duo (Android) 
 Diagnosis: Smartphone features for telehealth:  
Imaging (Camera)   
1. Black and White = infrared imaging for skin lesions for dermatology consultation 
2. Color photos: documentation of foot ulcerations, pressure ulcers by patients, skin infections, gum infections, 
cellulitis, color photos of eye infections. 
3. Measurement: built-in iOS app “Measure” for lesion size (Augmented reality) 
  
Conclusion:.  
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Type 2 diabetes self-management education is an essential component of type 2 diabetes care that is 
traditionally delivered in a face-to-face setting. In response to the COVID-19 pandemic, innovative 
solutions are urgently needed, allowing provision of self-management education that can be delivered in 
compliance with social distancing policies. Innovations that are self-service, and that can deliver education 
efficiently at low cost, are particularly appealing to healthcare providers and commissioners. 
  
Method: 
We developed and evaluated a free massive open online course in diabetes self-management education 
created and delivered during the COVID-19 pandemic. This course made use of online interactive content 
including expert and patient videos, quizzes, moderated discussion boards and live social media which 




N=1991 users registered interest in the course over a 2-week period, with N=976 users starting the course 
and N=640 (65.6%) users completing the course in full. Participants included people with type 2 diabetes 
(66.5%), people at risk of type 2 diabetes (2.6%), family members or caregivers of people with type 2 
diabetes (5.3%), and healthcare providers (28.8%). Users engaged well, finding the course educational, 
user-friendly, and motivating, demonstrating high completion rates and user satisfaction. A statistically 
significant (p <0.001) increase in both self-reported self-management ability and health knowledge was 
observed among participants with type 2 diabetes. 
  
Conclusion: 
Massive open online courses in type 2 diabetes self-management education have great potential for 
delivering education efficiently at scale and low cost. Although engagement can be limited by digital 
literacy, benefits include flexible and remote access to up-to-date, evidence-based, education delivered by a 
multidisciplinary team of healthcare providers. 
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Henrik Schou; Michael Stokes, MPH; Samuel Huse; Monica Bertolini, MD 
 
Endocrinology Division, Medical School and University Hospital, Universidad Autonoma de Nuevo Leon 
Monterrey, Nuevo Leon, Mexico 
leomancillas@uanl.edu.mx & leomancillas@gmail.com 
 
Objective: 
My Dose Coach (MDC), an FDA-approved smartphone application for individuals with type 2 diabetes, uses 
patient-recorded fasting blood glucose (FBG) data to provide basal insulin (BI) dose adjustments according to a 
healthcare professional-prescribed titration plan. This study investigates the impact on FBG reduction of MDC-
recommended BI adjustments. 
 
Method: 
Of N=411 registered MDC users in Mexico, N=278 individuals recorded ≥2 FBG readings over a 2-week period. 
N=218 (78.4%) reached individualized FBG targets and were included in outcomes analysis. Users were stratified as 
having decreased (N=22), increased (N=91), or maintained (N=99) BI dose; N=6 could not be classified. 
 
Result: 
Mean ± SD baseline FBG was 148.8 ± 65.7 mg/dL, age was 51.8 ± 12.5 years. Most participants (63%) were 
receiving U-300 glargine (Toujeo®) versus U-100 glargine (Lantus®) (37%). By the end of the study period, FBG 
decreased by 26% and mean time to target was 14.7 ± 16.0 days, with 0.3 ± 0.8 hypoglycemic events per participant. 
Mean BI dose increased from 28.1 to 31.2 U (+10%). The dose increase subgroup had higher initial FBG (190.5 ± 
75.2 mg/dL), and greater FBG change (-39%) reached in 23.1 ± 18.0 days compared to the stable dose (baseline 
FBG, 123.1 ± 33.0; FBG change, -12%; time to target, 7.6 ± 10.3 days) and dose decrease subgroups (baseline FBG, 
97.8 ± 39.3; FBG change, +8%; time to target, 10.6 ± 5.6). Hypoglycemic events per participant in each subgroup 
were 0.1 ± 0.3, 0.1 ± 0.5, and 1.7 ± 1.6, respectively. 
 
Conclusion: 
MDC, a digital titration solution for end-user health management, may help users to reach FBG targets with 
relatively low hypoglycemic risk by providing FBG-based BI adjustments. 
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Identification of Hepatic Clearance 
Parameters 
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Many metabolic tests require accurate identification of patient-specific parameters from data. Insulin assays are 
often used to identify insulin kinetics parameters, such as general and first-pass hepatic clearance values. This study 




Insulin and C-peptide data from two intravenous glucose tolerance test trials of healthy adults (N=10x2; denoted A 
and B), with insulin modification (A) and without an insulin bolus (B), were used to identify insulin kinetics 
parameters using a grid search.  Monte Carlo analysis (N=1000) quantifies the variation in identification error for 
insulin assay errors of 5%. A region of parameter pairs was identified around the optimal pair whose errors are 
within the 5% assay error variation. A larger region indicated poor identifiability and a smaller optimal region 
indicated more precise identifiability. Comparison of the two trials indicated if one method provides a more 
identifiable problem, and thus more precise results. 
 
Result: 
Trial B, without insulin boluses, has optimal parameter value regions 2.5x larger on average than trial A, with 
insulin boluses. The optimal parameter ranges between trials varies from 0.02 to 0.08 min-1 in general clearance, and 
0.06 to 0.09 in first-pass clearance on average.  
 
Conclusion: 
Addition of an 1U exogenous insulin bolus improves the identifiability of hepatic clearance parameters. Adding a 
small intravenous insulin bolus in metabolic tests significantly improves identification and outcome test precision. 
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Timed, and Timed-Insulin Dietary Glucose 
Disposal, (TGD(T,I) and TIGD(T,I), and 
Continuous Glucose Monitoring (CGM) 
 
John Stephens Melish, MD; John A. Burns  
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The objective is to refine carbohydrate counting (CC) and insulin administration using CGM and meal-related data 
to improve diabetic control, emphasizing the timing as well as the dosing of premeal insulin. 
 
Method:  
Two indices, TGD(T,I) and TIGD(T,I), were calculated utilizing CC with CGM meal-related time and the amount of 
insulin injected.  T refers to t1 – t0, time between t injection of insulin and initial rise above baseline of ingested 
carbohydrate.  I = amount of insulin injected at t0.  Interval from the rise and return to baseline of the glucose 
concentration curve = t3 – t2.  TGD(T,I)  = CC/t3-t2); TIGD(T,I) = CC/(t3-t2)*I.   CC comes from personal diet and 
insulin recording and reference materials.  Time intervals were obtained from the graphic CGM uploaded displays. 
 
Result:   
Example: Breakfast A equals Breakfast B: 6 strawberries, ½ cup uncooked oatmeal, ½ cup blueberries, ½ cup 
cottage cheese: 46 g glucose. Breakfast  A = TGD (0,13) = 46000/(180) = 256 milligrams/minute; TIGD (0,13) = 
46000/(180*13) = 19.7 mg/(min*unit)   Breakfast B: TGD (45,12) = 46000/45 = 1022 mg/min; TIGD = 
46000/(45*12) = 85.2 mg/(min*unit) 
 
Conclusion:  
These indices demonstrate the importance of the timing as well as the amount of insulin injected.  Clearly similar 
amounts of insulin injected at various times prior to a meal have a markedly different impact on the height and the 
duration of the glucose concentration curve.  Although the carbohydrate/insulin ratios were similar,  glucose 
concentration curves were clearly impacted by injecting insulin further away from the glucose concentration 
rise.  15-20 minutes is usually chosen as a time optimizing insulin effect while reducing the risk of 
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Impact of BGM Point Profiles on Glycemic 
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Julia Alyssa Mell; Anuar Imanbayev, BA, MS 
 
Data Science Summer Intern at Novo Nordisk from University of Washington 




Consistent measurements of the blood glucose levels in patients with diabetes are necessary in order to ensure the 
quality of the treatments administered. However, there is controversy over whether the emerging continuous glucose 
monitoring (CGM) devices are better than previous self-monitoring methods. This study investigates the effect that 
the number of blood glucose measurements taken per day has on a machine learning model’s ability to accurately 
predict three variations for the next day: the mean blood glucose value, the occurrence of a hypoglycemic event, and 
the time-in-range percentage. 
  
Method: 
Blood glucose monitoring (BGM) data from Novo Nordisk clinical trials was used to assess the machine learning 
prediction performances of 1, 4, 7, and 9-point profiles (PP) in comparison to CGM data. Performance was 
measured by accuracy metric for classifier models and R-squared metric for regressor models. The machine learning 
models tested included support vector machine, gradient tree boosting, and random forest. Linear regression for 
regressor and logistic regression for classifier were used as baseline comparison models. 
  
Result: 
Mean blood glucose value: 1PP – 78.14%, 4PP – 45.07%, 7PP – 92.98%, 9PP – 98.96%. Hypoglycemia event: 1PP 
– 95%, 4PP – 69%, 7PP – 84%, 9PP – 99%. Time-in-range percentage: 1PP – N/A, 4PP – 16.40%, 7PP – 76.66%, 
9PP – 98.62%. 
  
Conclusion: 
BGM data can perform equivalently to CGM data, with the most consistently accurate predictions corresponding to 
the 9PP. However, a 9PP is not the most viable option, since it would require patients to prick their fingers 8 times 
per day. Further analysis of the deficiencies and inaccuracies in lower point profiles is required in order to 
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Workplace exposure in various occupational and industrial sectors is an emerging health concern worldwide. This 
study aimed to investigate the workplace exposure for various occupational and industrial workers and prevalence of 
prediabetes and type 2 diabetes mellitus.  
 
Method:  
Initially, N=2500 male volunteers who were wood, welding, motor mechanic, and oil refinery workers were 
interviewed. After an examination of their demographics and medical history, N=1408 total workers: non-smoking 
wood (N=158), welding (N=560), motor mechanic (N=272), and oil refinery workers (N=217), along with N=201 
control subjects, were selected. These workers had been exposed to their respective workplaces for 8 h per day, six 
days per week.  
 
Result:  
Subjects with an A1c of less than 5.7% were regarded as non-diabetics, A1c 5.7%-6.4% were considered 
prediabetics, and subjects with A1c more than 6.4% were considered diabetics. In wood industry workers, the 
prevalence of prediabetes (PD) was N=64 (40.50%), T2DM N=21 (13.29%); in welding workers, prediabetes was 
N=261 (46.60%), and T2DM was N=90 (16.07%); in motor mechanic workers, prediabetes was N=110 (40.44%), 
and T2DM was N=126 (46.32%); and in oil refinery workers, the prevalence of prediabetes was N=80 (36.86%), 
and T2DM was N=35 (16.12%). However; the combined prevalence of prediabetes and T2DM among wood, 
welding, motor mechanic, and oil refinery workers was N=421 (34.79%) and N=515 (42.66%), respectively.  
 
Conclusion:  
The prevalence of prediabetes and T2DM among various industrial workers increased with the duration of working 
exposure in the wood, welding, motor mechanic, and oil refinery industries. A one-year working exposure in these 
industries caused an increase of 0.03% in A1c.  
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SGLT2 Inhibitor Interference Testing with 
Accu-Chek® Blood Glucose Monitoring 
Systems 
 
Kacia Mills, BS; Ingrid Keth; Brian Huffman, PhD; Jochen Schulat, PhD  
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The objective of the study was to evaluate the performance of five Accu-Chek blood glucose monitoring systems in 
the presence of elevated concentrations of four SGLT2 inhibitors:  canagliflozin (Invokana®), dapagliflozin 
(Farxiga®), empagliflozin (Jardiance®) and ertugliflozin (Steglatro®).  SGLT2 inhibitors are commonly used in the 
treatment of type 2 diabetes and remove sugar from the body through the urine.  The systems included in the study 




A literature search was conducted to determine peak plasma concentrations of the four medications, and samples 
were prepared at five times the peak plasma concentrations of each medication.  Test and control samples were 
prepared in whole blood at three glucose concentrations, and three strip lots were tested per system. 
 
Result: 
The samples were prepared per CLSI’s EP07 Interference Testing in Clinical Chemistry, 3rd edition, and the 
substances were tested at the following target concentrations: canagliflozin (1.7 mg/dL), dapagliflozin (0.1 mg/dL), 
empagliflozin (0.3 mg/dL) and ertugliflozin (0.2 mg/dL).  The bias between the test and control samples was 
calculated for each substance at each glucose level.  The bias results were then evaluated against the acceptance 
criteria in ISO 15197:2013/EN ISO 15197:2015, which state that a substance is considered an interferent if the mean 
bias exceeds 10 mg/dL for glucose concentrations less than 100 mg/dL or exceeds 10% for glucose concentrations 
greater than or equal to 100 mg/dL.  At the concentrations tested, canagliflozin, dapagliflozin, empagliflozin and 
ertugliflozin are not considered interfering substances with the Accu-Chek® systems in the study 
 
Conclusion: 
When using any of the four tested SGLT2 inhibitors, blood glucose results from the five tested Accu-Chek systems 
will not be biased. 
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The decision when to intensify the treatment from oral treatment to basal insulin is made by the health care 
professional for people with type 2 diabetes (T2D). In this context, treatment intensification relies heavily on the 
A1c test. Although several alternative oral treatments exist, basal insulin remains in general one of the most 
effective solutions for both treatment and cost for people with T2D. Hence, knowing at onset if basal treatment is the 
most suitable for treatment intensification for a patient is of high relevance. The aim of this study is to examine to 
what extent patient demographics and continuous glucose monitoring (CGM) data can enhance the ability to predict 
treatment outcome beyond what can be predicted based on A1c alone at treatment onset. 
 
Method: 
Clinical data were acquired from four different trials with a total of N=222 poorly regulated people with T2D 
(A1c ≥ 7%) on oral treatment initiating once-daily insulin injection. A1c, demographics, and expert-dependent 
CGM metrics (3 days) were available at onset. Logistic regression was used in a repeated stratified cross-validation 
setup to evaluate the performance predicting the binarized A1c value after 6 months defined as either acceptable 
(A1c < 7%) or poor (A1c ≥ 7%). 
 
Result: 
In all cases the performance exceeds the baseline (majority class) in terms of prediction accuracy. Adding 
demographics and CGM metrics as input to the models in the cross-validation setup improve treatment outcome 
predictions contrasted to using A1c alone at onset. 
 
Conclusion: 
The obtained results indicate improved performance when enhancing the input to the prediction models with 
demographics and CGM metrics in addition to A1c at onset. This points to demographics and CGM data being 
useful for the assessment of successful/unsuccessful treatment outcomes. 
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mHealth applications have the potential to improve glycemia and the overall health status of people with diabetes. 
However, some patients only minimally engage with these technologies and thus achieve suboptimal clinical 
outcomes.  The goal of this study is to build a predictive model that, given early usage data from a diabetes mHealth 




A sample of N=238 type 2 diabetes patients were recruited via email to begin using a diabetes management mHealth 
application. The first 2 weeks of engagement data, as well as demographics, were collected and used as independent 
variables. Logistic discriminant analyses were run with consistent user persistence and a drop in either average or 
maximum BG as dependent variables. The BG value 14 mg/dL was used since it represents a change of 
approximately 0.5% A1C points. 
 
Result: 
Logistic discriminant analysis was able to predict users’ consistent persistence at the month 3 and month 6 
timepoints with 81.6% accuracy. A 14 mg/dL drop in either max or average BG at the month 3 and month 6 
timepoints could be predicted with 79.8% accuracy. 
 
Conclusion: 
This study shows that it is possible to predict which users will consistently persist in using a diabetes mHealth 
application and/or experience an improvement in BG from just 2 weeks of initial usage data. Future research may 
potentially explain the factors affecting users likely to drop out or experience limited clinical improvement. 
Automated and early identification of patients unlikely to succeed in a mHealth protocol provides an opportunity to 
target these users with additional interventions to get them on track. 
 
  
DTM 2020 Abstracts A447DTM 2020 Abstracts  A51 
 
Significant Reduction in Time-Below-Range 
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Hypoglycemia remains a significant concern around intensive glucose management for people with diabetes (PWD). 
Advanced hybrid closed-loop systems like Control-IQ technology can provide opportunities to assist PWDs better 
manage their time-below-range (TBR) or hypoglycemia while optimizing glycemic control.   
 
Method: 
This study was part of a larger project evaluating real world outcomes in early adopters of Control-IQ technology. 
We examined sensor TBR metrics for PWDs with type 1 diabetes (T1D) 30 days prior to starting Control-IQ 
technology (T1) and after 7 weeks of Control-IQ technology use (T2). Assessment of TBR metrics was guided by 
international guidelines i.e. <4% time/day with sensor reading (SR) <70mg/dL (Level 1) and <1% time/day with SR 
<54mg/dL (Level 2). Glycemic data was captured from the t:connect® web application. Wilcoxon-signed rank tests 
were performed to analyze change in median (IQR) TBR, and time-in-range (TIR) from T1 to T2.  
 
Result: Of N=1127 participants at T1, N=232 PWDs were not meeting the TBR recommended guidelines. They 
were significantly more likely to be male, have longer diabetes duration, lower body weight, lower A1c, and better 
TIR compared to their counterparts who met TBR recommendations at T1 (n=895). For the N=232 PWDs, with 
Control-IQ technology use, significant reduction in TBR was noted at T2 for Level 1 (4.75% (2.94-6.66%) to 3.04% 
(1.63-4.62%)) and Level 2 hypoglycemia (0.86% (0.40-1.43%) to 0.54% (0.21-1.01%)), p<0.001. Overall, 
participants spent 24.6 minutes less/per day in Level 1 hypoglycemia and 4.6 minutes less/per day in Level 2 
hypoglycemia at T2. Their TIR improved significantly from 76.95% (69.42-83.87%) (T1) to 83.74% (77.17-
88.71%) (T2) (p<0.001).     
 
Conclusion: 
Control-IQ technology demonstrated a clinically relevant reduction in hypoglycemia with improved TIR in PWDs 
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Recently (Noaro et al., IEEE TBME, 2020), we proposed a new model for mealtime insulin dosing in type 1 
diabetes (T1D) management based on least absolute shrinkage and selection operator (LASSO). We demonstrated, 
both in silico and using available clinical data, that the new model outperforms the current standard formula (SF) for 
insulin dosing used in common clinical practice. The aim of this work is to further validate the new LASSO model 
using a new independent dataset before moving onto ad hoc clinical trials. 
 
Method: 
Data collected during the CTR3 study (ClinicalTrials.gov ID: NCT02137512) were preprocessed by analyzing the 4-
hour postprandial intervals where no corrective actions (e.g. hypotreatments or corrective boluses) were present. The 
selected data segments were divided into two different scenarios based on the glucose trend arrow (ΔG) at mealtime, 
i.e., increasing and decreasing ΔG (scenario A and B respectively). Then, to assess the efficacy of the LASSO model 
against SF, we applied ReplayBG, i.e., a newly proposed in-silico framework for the assessment of new therapy 
guidelines for T1D management using retrospective data.   
 
Result: 
Results in terms of percentage of time in the hyperglycemic, euglycemic, and hypoglycemic range were consistent 
with the results achieved in our paper, thus confirming the efficacy of our method. Specifically, compared to SF, we 




In conclusion, the results obtained in this work confirm the positive impact of our new LASSO model for mealtime 
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Utilizing the patented “MCAL” chipset design to prototype a biomimetically-designed multilayer-chipset for 
development of “mIslets” which have important features: 1)continuous blood perfusion 2)maintaining 
immunoisolation 3)providing nutrients and oxygen to satisfy the Islets’ metabolic demands, and 4)allowing 
diffusion of insulin into the plasma. Compilation of “mIslet” biochipsets produces the wearable and implantable 
bioartificial pancreas-“mPancreas”.  
 
Method: 
Chipsets were fabricated by sandwiching two PES-membranes (20kDa MW Cutoff) in between three microfluidic 
layers, creating a central layer to be used as an islet reservoir that provides immunoisolation.  Blood perfusion via 
the outer layers allowed oxygen, glucose, nutrients and molecules [<20kDa such as insulin(MW-5.8kDa) and 
glucagon(MW-3.5kDa)] to diffuse to the blood based on patient’s glucose level.   
 
Result: 
In experiments, anticoagulated bovine blood flowed through middle layer without cell damage, while serum-like 
fluid flowed through the two outer layers and significant diffusion of different size molecules (Creatinine, 
Phosphorus and Vitamin B12) occurred rapidly and continuously in between these three layers demonstrating that 
oxygen, glucose, insulin and glucagon can be exchanged if they are < 20kDa.  This proof of concept would allow 
these 3D-structure chipsets to be populated with Islet that are perfused with blood providing the oxygen, nutrient, 
glucose, to the middle layer that contains islet or stem cells.  
 
Conclusion: 
We introduce a novel and biomimetically-designed three-layer microfluidic chipset with  unique features providing 
continuous low blood flow to provide oxygen and nutrients through diffusion to the islets in an immunoisolated 
niche. These chipsets will be used to develop the “mIslet” chipsets to release insulin based on patient’s glucose level 
emulating a pancreas. The compilation the “mIslets” will produce the wearable and/or implantable Bio-Artificial 
Pancreas termed “mPancreas” emulating true pancreas. 
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The purpose of this study was to examine the prevalence, acceptability, and potential for using digital health tools 
(smartphones and health apps) in health promotion for people with diabetes mellitus. 
  
Method:  
Data were pooled from cycle 3 (2019) of the 5th edition of the Health Information National Trends Survey (HINTS 
5). Descriptive statistics were used to investigate the prevalence of smartphones and health apps ownership. The 
difference between health apps ownership versus non-ownership was examined among individuals with diabetes 
with regards to perceived usefulness of digital tools for managing their health, and intentions to adopt positive health 
behaviors using chi-squared tests.  Multivariable logistic regression was used to identify sociodemographic 
predictors of health app ownership. 
  
Result:  
A total of N=1149 participants (21.7%) who self-reported diabetes mellitus was identified. The prevalence of digital 
health tools ownership was 77.7%, 53.8%, and 46.3% for smartphones, tablets, and mobile health apps respectively. 
Individuals with diabetes mellitus who had health apps installed on their devices were more likely to report 
intentions to lose weight than those without health apps. Further, they were also more likely to find these devices 
beneficial for health promotion. Of all the sociodemographic predictors, only the level of education significantly 
predicts health app ownership. 
  
Conclusion:  
Digital health tools have been accepted and are already being utilized by individuals with diabetes mellitus for self-
care. In our study, the prevalence of health app ownership among those with diabetes is 46.3%. Education was an 
important predictor of health app ownership. This information is crucial and underscores the need to address 




DTM 2020 Abstracts A451DTM 2020 Abstracts  A55 
 
Use of Wearable Device among Adults in the 
US with Self-reported Diabetes Mellitus: An 
Analysis of the 2019 Health Information 
National Trends Survey 
 
Kesiena Onoriode, MD, MPH; Henry Onyeaka, MD, MPH; Victor Kekere, MD, MS; Olubunmi 
Fatoki, MD, MS; Kudirat Olatunde, MBBS, MHA; Somto Enemuo, MBBS, MPH; Chidi Asuzu, 
MBBS; Oluwadamilola Obawede, MD; Claudia Gyimah, MD; Ihechiluru Nzeako, MD 
 
Texas A&M University 




The objective of this study is to evaluate the prevalence, patterns, and sociodemographic predictors of wearable 
device use among individuals with self-reported diabetes mellitus.  
  
Method:  
Data for our analysis was drawn from cycle 3 (2019) of the 5th edition of the Health Information National Trends 
Survey (HINTS 5). Descriptive statistics were used to evaluate the demographic characteristics, prevalence, and 
frequency of wearable device use among individuals with diabetes mellitus. Multivariable logistic regression was 
used to identify the sociodemographic predictors of wearable device use.  
  
Result:  
We identified N=1149 individuals who self-reported diabetes mellitus. Of these, 51.2% were females, 59.3% were 
white, and 51.6% had less than a college education. The prevalence of wearable device use was 20%. Further, a 
large proportion (86.1%) of the wearable device users were willing to share information from their wearable devices 
with their healthcare provider, and almost half of them (43.4%) reported daily use of these devices in the past 1-
month. Significant sociodemographic predictors of wearable device use include age, income, and level of education. 
  
Conclusion:  
Our results highlight the feasibility and acceptability of using wearable devices to deliver evidence-based health care 
to individuals with diabetes. Future interventions should consider the scalability of these tools and how to reach 
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Direct measurement of pancreatic insulin secretion is difficult from insulin assays alone, as inter-subject variability 
in hepatic extraction and peripheral clearance make it unidentifiable. C-peptide does not have the same 
physiological constraints and is commonly used to calculate insulin secretion using the well-known Van Cauter 
model. However, this model uses fixed relationships for three key model parameters, built from their study data, but 




Data was analyzed from N=39 healthy male subjects in a frequently-sampled intravenous glucose tolerance test 
(ivGTT). C-peptide values were used to calculate insulin secretion using Van Cauter’s kinetic parameters. Monte 
Carlo analysis independently varied all three parameters within reported ranges, yielding N=10,000 combinations 
per subject (based on convergence analysis). Insulin secretion area under curve (AUC) represents total secreted 
insulin over first and second phase within the 40 minute test. Per-subject median AUC is what Van Cauter’s model 
calculates. Normalizing each AUC by the participant’s median value over all N=10,000 iterations quantified the 
expected model-based variability in AUC. 
 
Result: 
Median AUC was 5,741 mU and ranged from 2,761 mU – 13,858 mU across all subjects. Normalized per-subject, 
AUC ranged from 81% to 120% (25th-75th range) of the median value. Thus, Van Cauter modeled insulin secretion 
may vary by up to ±20% across all subjects from the standard model calculation. AUC total insulin variation was 
reflected in both first and second phase secretion. 
 
Conclusion: 
Kinetic parameters first proposed by Van Cauter  may easily over or under-estimate insulin secretion from C-peptide 
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Creation and adoption of clinical data standards that support diabetes technology data will transform incompatible 
and disparate data into universal and illuminating information, facilitating discoveries that could have invaluable 
impact on T1D clinical research. Implementation of CDISC standards allow collection, organization, and analysis of 
data in a clear and consistent manner allowing all researchers to leverage information from studies globally.  
 
Method: 
With support from The Leona M. and Harry B. Helmsley Charitable Trust, CDISC is leading a unique, consensus-
driven effort, bringing together T1D experts from academia and industry, to build on existing CDISC diabetes 
standards to create T1D clinical data standards in pediatrics, devices, exercise, nutrition and screening, staging, and 
monitoring of pre-clinical T1D. 
 
Result: 
In September 2020, pediatrics and devices standards are published at https://www.cdisc.org/standards/therapeutic-
areas and freely available. Data models and standard formats have been developed that can represent the following: 
- Identification of all devices and components for management of T1D 
- Device properties and settings 
- Participant utilization of devices 
- Device events and user experience (e.g., DKA, Hypoglycemia etc.) 
- Diabetes History 
- Vital Signs and Growth Percentiles 
- Pubertal Status 
Additional standards related to T1D are due for publication towards the end of 2020. 
  
Conclusion: 
To make the greatest impact on T1D research, widespread promotion of the availability of standards for researchers 
to adopt and implement is of highest importance. CDISC provides complementary education courses and 
implementation information to assist in this adoption. Widespread adoption of the standards will bring clarity to 
T1D data and will enable the accessibility, interoperability, and reusability of data, driving operational efficiencies, 
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Telehealth:  
Keeping Young People with Type 1 Diabetes 
Mellitus Connected to Healthcare during the 
COVID-19 Pandemic 
 
Anne Parkinson, BA (Hons), PhD; Nicola Brew-Sam BA, MA, PhD; Sally Hall Dykgraaf, RN, Grad 
Cert Clin Man, PhD Candidate; Christopher Nolan, BMedSci, MBBS, PhD, FRACP; Tony 
Lafferty, MB, ChB, FRACP; Robert Schmidli, MB ChB, PhD, FRACP, MRCP; Maria Cecilia 
Garcia Rudaz, MD, PhD, FRACP; Ellen Brown; Karen Brown, RN; Lachlan Pedley; Jane 
Desborough, RN, RM, MPH, PhD 
  
Department of Health Services, Research and Policy, Australian National University 




To examine the experiences of young people with type 1 diabetes mellitus (T1DM) in accessing healthcare during 
the COVID-19 pandemic in Australia. 
 
Method: 
A qualitative methodological approach was used involving semi-structured interviews (n=11) and thematic analysis. 
A purposive sample of young people aged 12-16 years with T1DM (accompanied by a parent) were interviewed via 
Zoom or telephone between June and July 2020. Interviews lasted 20-40 minutes and were recorded and transcribed. 
 
Result: 
Three key themes were identified: feeling vulnerable; new ways of accessing care; and feeling well-supported by the 
healthcare team. Participants were aware that T1DM made them more vulnerable to poor outcomes if they 
contracted COVID-19. In some cases, due to this, usual face-to-face care was postponed or not sought. Participants 
relied on three-monthly appointments with the diabetes healthcare team to review and plan their diabetes 
management. Telehealth consultations offered a convenient and contactless way to continue this. The greatest 
differences were not having access to the whole team at one appointment (endocrinologist, dietitian, diabetes 
educator, psychologist), or to physical examination and A1c testing during telehealth consultations. However, 
participants were secure in the knowledge that they could contact team members via email or telephone for advice 
and trusted their team to advise them if a face-to-face consultation was necessary. Some felt a video option might be 
better than telephone. Most participants considered using telehealth for some, but not all, consultations with the 
diabetes health service as part of their future healthcare routine. 
 
Conclusion: 
Telehealth consultations offer convenient, safe, and contactless access to healthcare professionals during COVID-
19.  The added value of video consultations and whole team access need to be considered for future clinical 
implementation of telehealth. 
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Pulsatile Insulin Treatment as a Treatment 
Option for Patients with Type 2 Diabetes and 
Stage III Kidney Failure – Results from a 
Pilot Study 
 
Andreas Pfützner, Mina R. Hanna, Daniela Sachsenheimer, Yuriko Andor, Linda Do, Jessica Liu, 
Sol Steiner, Stephen McCormack, Anastasios Manessis 
 





In healthy individuals, insulin is secreted by the pancreatic ß-cells in a pulsatile fashion with about 10-12 
pulses/hour. Loss of this pulsatility is one of the first indications of ß-cell dysfunction leading to type 2 diabetes. 
This pulsatility of insulin secretion is considered a trigger mechanism for the regulation of hepatic gluconeogenesis 
and for maintaining the sensitivity of peripheral metabolic and vascular insulin receptors. Various attempts have 
been made over the last 30 years to use pulsatile intravenous (iv) insulin infusion therapy (PIT) for treatment of 
diabetes and secondary complications.  The purpose of this prospective, randomized pilot study was to investigate 
the effect of once weekly PIT (2 h vs. 3 h procedures) over a period of 3 months on parameters of kidney function in 
patients with type 2 diabetes and chronic renal failure (glomerular filtration rate (GFR) < 60 mL/min). 
 
Method: 
Of the N=22 enrolled type 2 patients, N=17 performed the trial per protocol (7 women, 10 men, age:  69±7 yrs., 
A1c: 7.9±1.0 %). They received a total of 10 PIT procedures (2h: 9 patients/3h:8 patients). Observation parameters 
measured at baseline and endpoint were A1c, glomerular filtration rate (GFR) using the MDRD formula, body 
weight, blood pressure, creatinine, nerve perception thresholds (pain, warm, cold, vibration, assessed by path tester), 
and treatment satisfaction (DTSQ).  
 
Result: 
At endpoint, there were no significant differences between the two groups, and the final results are presented for the 
whole population. GFR improved by 12 % (from 47.6±10.0 mL/min to 53.3±11.9 mL/min, p<0.01) and creatinine 
decreased by 7 % (1.43±0.29 mg/dL vs. 1.33±0.34 mg/dL, p<0.05). Stable results were seen for A1c (-0.1%), body 
weight (-0.5 kg) and blood pressure (systolic/diastolic: -4%/0%, all n.s.). No changes were seen in nerve perception 
thresholds for any of the investigated sensory fiber qualities. The sum score for treatment satisfaction improved from 
3.6±2.3 to 2.9±2.1 at endpoint (p<0.05). The treatments were well-tolerated; however, 8 treatment-related events of 
muscle cramps were reported for N=5 patients during the PIT procedures. 
 
Conclusion: 
In conclusion, an improvement in kidney function and treatment satisfaction was observed after 3 months of PIT in 
patients with type 2 diabetes and renal failure, irrespective of the duration of the procedure (2h vs. 3h). The results 
of this pilot trial will now be used to design an appropriate confirmatory study to investigate the effect of PIT when 
given in addition to standard of care treatment vs. standard of care alone.    
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Use of the Sencell Osmotic Pressure-Based 
Glucose Sensor in a Standard Needle Sensor 
Environment 
 
Andreas Pfützner, Malte Bartenwerfer, Sanja Ramljak, Joacim Holter, Rune Frisvold, Konstantin 
Kloppstech, Frank Flacke 
 





The size of the measurement chamber of the injectable Sencell Glucose Sensor (Lifecare, Norway) is smaller than 
0.7 x 0.35 x 0.7 mm³. It uses an active fluid with a glucose binding molecule (GBM) and a glucose-like ligand to 
transfer external glucose concentrations into measurable osmotic pressure signals. The reversible affinity reaction in 
the chamber does not consume any molecule when generating the signal, resulting in a potential for long-term 
survival of the sensor in the body. The small size of the sensing element allows also for integration into a standard 
needle sensor environment.    
 
Method: 
The miniaturization of the sensor without losing pressure sensing sensitivity was achieved by a proprietary, 
nanosensor technology. Micro-electromechanical systems (MEMS) fabrication techniques were used to build a 
sensor chamber with less than 1 mm³ volume and the pressure membrane was equipped with nano-strain sensor (4 x 
1 µm²). For preparation of needle sensor prototypes, the chamber was embedded into a steel needle and connected 
by wire to an electronic read-out interface. Sensor calibration was performed over a broad dynamic glucose 
concentration range.  The observed sensor specifications (pressure range: <-300 to >300 mbar, pressure resolution 




The collected signals showed a very sensitive and linear pressure to signal relation (r²=0.996), a high reproducibility 
(CV = 0.2 %), no hysteresis/drift over time, and a high stability even when performing continuous repetitive 
calibration procedures.  
 
Conclusion: 
In conclusion, needle sensor prototypes based on the core Sencell sensor technology have been developed, which 
could be potentially integrated into existing needle sensor products. This could enhance longevity and accuracy by 
providing orthogonal glucose signals, which could be used for cross-calibration. Clinical studies with the prototypes 
to test the in-vivo performance of the technology have been initiated. 
  
  
DTM 2020 Abstracts A457DTM 2020 Abstracts  A61 
 
Insulin Pump Therapy Is Useful for Type 1 
Diabetes Regardless of Variable 
Demographics 
 
Muhammad Asif Rao, MBBS; Thinn Yu, MBBS M.Med.Sc; Rosie Hattersley, MBBch; Melanie 
Nana, MBBch; Kofi Obuobie, MD, MBBS 
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Insulin pump therapy has demonstrated benefits in terms of glycemic optimization and patient satisfaction. 
However, despite being a technologically advanced insulin delivery system it requires substantial input from its 
users to work optimally. This can be influenced by several demographic variables of the user population. This study 




This retrospective observational study included all patients with type 1 diabetes who attended the insulin pump 




N=108 patients were included in the study with a mean age of 41.25 years (SD 14.547 years). The mean pre-pump 
A1c was 66.08 mmol/mol (SD 14.32 mmol/mol). In total, N=97 patients had an A1c 6-months post-pump initiation 
(mean 60.26 mmol/mol); N=66 patients 12-months post (mean 60.17 mmol/mol) and N=56 patients 18-months 
(mean 60.64 mmol/mol). In total 31/108 (28.7%) patients had previous experience with a pump. 
 
Conclusion: 
This study demonstrated trends towards an improvement in A1c that was sustained at 18-months. These trends were 
observed in patients regardless of their hospital site, previous experience with pump therapy, or age. Larger studies 
are required to confirm these results but our work supports pump therapy being offered to a wide demographic 
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Clinical Relevance of Reapplication of Blood 
Samples During Blood Glucose Testing 
 
James M Richardson, MPharm, MBA; Scott Pardo, PhD, PStat®; Rimma Shaginian, MD, MPH 
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Second-Chance™ Sampling (SCS) is a feature of some BGMSs that allows users to apply more blood to the test 
strip if the first attempt had insufficient volume, reducing the need to re-lance.  Utilization of SCS has not been 
examined outside of a registrational trial setting.  This analysis utilizes CONTOUR®DIABETES app (CDA) cloud 
data and examines the use of SCS and if there are differences between patient groups based on patient reported data.  




A retrospective observational analysis was performed on worldwide CDA users in February 2020.  ANOVA was 
performed on SCS users for several variables including diabetes type, therapy, age and gender.  Additionally odds 
ratios were calculated to assess whether the probability of using SCS was greater when blood glucose values were 
above or below 70 mg/dL. 
 
Result: 
Significant differences in percent of SCS use were observed for diabetes type (P=0.0019), age (P<0.0001), gender 
(P< 0.0001) and therapy profile (P=0.0019).  SCS use was more likely when blood glucose was below 70 mg/dL 
than above 70 mg/dL (OR 1.4, 95% CI 0.9965, 1.8318). 
 
Conclusion: 
Utilization of SCS differs depending on diabetes type, gender, age and therapy.  SCS can reduce the need to re-lance 
and prevent the waste of up to 12.68% of test strips in specific patient groups.  Therefore BGMS’s with SCS feature 
should be considered particularly for patients who use SCS the most. 
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Glycemic Outcomes with Adjustable Settings 
in the Advanced Hybrid Closed-loop (AHCL) 
System-Pivotal Trial 
 
Anirban Roy, PhD; Benyamin Grosman, PhD; Ronald Brazg, MD, FACE; Bruce Bode, MD; Satish 








The MiniMed™ AHCL algorithm has several important advances over the MiniMedTM 670G algorithm including 
upgraded safety features, two user-adjustable basal target (BT) setpoints, and an automated correction bolus feature 
(the aggressiveness of which can be adjusted by changing active insulin time [AIT]). We evaluated the effects of 
various BT and AIT settings on glycemic outcomes. 
 
Method:  
A post-hoc analysis of data from a multi-center, single-arm pivotal trial (N=157 participants with T1D, 14–75 years) 
that had a ~2-week baseline period and a 90-day study period (AHCL algorithm engaged) was conducted. At ~45 
days into the study period, participants switched BT from 100 to 120mg/dL, or vice-versa. The impact of BT and 
AIT on percentage of time spent below range (TBR<70mg/dL) and within range (TIR70-180mg/dL) was assessed. 
 
Result:  
Data were stratified by BT and further divided into four groups based on AIT (2, >2–3, >3–4, and >4 hours). To be 
included in the analysis, 14 consecutive days of SG-data were required after a BT and/or AIT change. There were 12 
cases with the most aggressive settings (100mg/dL BT and 2-hour AIT) where the average(SD) of TIR and TBR 
were 78.5%(7.1%) and 2.9%(2.0%), respectively. Conversely, 33 cases were identified with the least aggressive 
settings (120mg/dL BT and >4-hour AIT) where similar metrics were 71.6%(6.6%) and 1.1%(0.8%), respectively. 
There were no episodes of severe hypoglycemia or DKA in any group.  
 
Conclusion:  
The data show that the AHCL algorithm is safe and effective across the spectrum of BT/AIT settings studied. The 
TIR increased by 6.9% with a slightly increased TBR that remained below 4%, at the most aggressive setting, 
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Diabetes Mobile Apps and COVID-19 
 
Kaelan Samoranos, B.S; Chap-Kay Lau, B.S.; Gloria Wu, MD 
 
University of California: San Diego 




Do diabetes apps contain accessible information about COVID-19 and its symptoms? 
 
Method: 
Using the search term “diabetes,” the top ten most downloaded android and iOS apps were assessed in the Google 
Play Store/Apple App Store, respectively. Inclusion criteria: 1) Android: Downloads > 100,000; iOS: Reviews > 300 
2) Free 3) Ability to track health data: A1C and FBS. Language Accessibility: Checked for in-app language settings; 
if none, changed language setting on device. 
 
Result: 
In the Play Store, the top ten apps in descending order were: 1) mySugr, 2) Onetouch Reveal, 3) OneDrop Diabetes 
Management, 4) Diabetes: M, 5) Health2Sync - Diabetes Care, 6) Diabetes, 7) Ontrack Diabetes, 8) Blood Glucose 
Tracker, 9) Glucose Buddy Diabetes Tracker, and 10) Diabetes Connect. In the App Store, the top ten apps in 
descending order were: 1) OneTouch Reveal, 2) Glucose Buddy Diabetes, 3) One Drop for Diabetes, 4) Glucose - 
Blood Sugar Tracker, 5) Blood Sugar Monitor by Dario, 6) mySugr, 7) Sugarmate, 8) DiabetesPal, 9) Diabetes:M, 
10) Center Health - The Diabetes App.  Of the ten Android apps: 0/10 had COVID symptom information in the app; 
3/10 had a COVID statement; In-app language settings: 2/10 had Spanish and 1/10 had Chinese; After changing 
device language settings: 4/10 had Spanish and 1/10 had Chinese.  Of the ten iOS apps: 0/10 had COVID symptom 
information in the app; 4/10 had a COVID statement (Only mySugr has CDC link for COVID information); In-app 
language settings: 1/10 had Spanish and 0/10 had Chinese settings; after changing device language settings: 5/10 
had Spanish; 3/10 had Chinese. 
 
Conclusion: 
Of the top 20 diabetes apps, none of them had any information about COVID and its symptoms in the app. Also, the 
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Classification of Daily Continuous Glucose 
Monitoring (CGM) Profiles in Type 1 
Diabetes Using Layered Clustering and 
Clinical Metrics 
 
Mahdi Shafiei, PhD; Leon Farhy, PhD; Benjamin Lobo, PhD; Boris P. Kovatchev, PhD 
 
Center for Diabetes Technology, University of Virginia 




The objective of this study is to propose a new methodology classifying CGM profiles into a limited number of 
distinguishable classes with unique clinical characteristics in order to assist with the interpretation of CGM data. 
 
Method: 
CGM daily profiles were derived from two clinical studies of the International Diabetes Closed-loop Trial, DCLP1 
and DCLP3, recruiting N=127 and N=168 patients with T1D, respectively. Each 24-hour midnight-to-midnight 
CGM profile was partitioned into 8-hour non-overlapping intervals, clustered in a layered manner using K-means 
based on mean CGM (high vs low) and variability (high vs low Hourly Risk Range) to generate 64 clusters. Cluster 
centroids were determined from DCLP1 data (training set) and then used to classify the CGM profiles of DCLP3 
(testing set).  
 
Result: 
Good cluster separation was observed in DCLP1 (mean cluster overlap of 34±16%) and confirmed by DCLP3 
(mean overlap 37±18%). The classifier robustness was further confirmed by showing that corresponding clusters 
originating from the training and testing sets had similar shape (overlap 77±10%). In line with previously reported 
clinical outcomes (NEJM, October 2019), the classifier distinguished well DCLP3 patients on closed-loop control 
(CLC, N=112) vs. those on sensor-augmented pump (SAP, N=56), with 44% of profiles on CLC vs 36% of profiles 
on SAP classified in the clusters with lowest variability. 
 
Conclusion: 
A novel method for classification of daily CGM profiles generated a limited number of classes distinguishable by 
their shape and clinical characteristics. The methodology can distinguish between different treatment modalities and 
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Impact of the MiniMed™ AHCL System on 
Post-prandial Glucose after a Missed Meal 
Bolus in Adolescents and Adults with Type 1 
Diabetes (T1D) 
 
Jennifer L. Sherr, MD, PhD; Dorothy I. Shulman, MD; Robert H. Slover, MD; Anders L. Carlson, 
MD; Mark S. Kipnes, MD; Melissa Vella, BSc; Fen Peng, MD; John Shin, PHD, MBA; Toni L. 
Cordero, PhD; Andrew Rhinehart, MD, FACP, FACE, CDE, BC-ADM 
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Missed meal boluses are not uncommon and often result in hyperglycemia. This exploratory study assessed effects 
of the MiniMed™ AHCL system that autocorrects to 120mg/dL every 5 minutes on sensor glucose (SG) after a 
missed meal bolus, during the system pivotal trial in individuals with T1D. 
 
Method:  
Pre-prandial and post-prandial data from N=18 adolescents (14-21yrs) and N=66 adults (22-75yrs) were compared 
after a missed bolus for a dinner meal (±30% carbohydrate difference) on one day during a 2-week run-in and 90-
day study phase (at basal target [BT] 100mg/dL). Differences in SG, time spent above range (TAR>180mg/dL and 
TAR>250mg/dL), within range (TIR70-180mgd/dL), and other metrics between run-in and study were determined. 
 
Result:  
Study phase Auto Bolus initiation reduced post-prandial SG after a missed meal bolus by 49.3% and 58.0% at 0-
2hrs and 0-4hrs post-meal, respectively, for adolescents; and by 17.8% and 30.5%, respectively, for adults. Peak SG 
was reduced by 49.8% and 52.6%, respectively, for adolescents; and by 24.3% and 29.6%, respectively, for adults.  
In adolescents, the meal-induced increase in TAR>180mg/dL was lowered by 56.9% and 54.2%, respectively; and 
that in TAR>250mg/dL by 52.0% and 65.4%, respectively. In adults, the increased TAR>180mg/dL and 
TAR>250mg/dL were lowered by 20.2% and 36.3%, respectively; and by 35.3% and 47.5%, respectively. At each 
post-meal period, adolescent and adult post-prandial TIR improved by 50.9% and 49.1% and by 35.5% and 45.2%, 
respectively, compared to run-in. The run-in and study post-prandial TBR for each group was reduced. 
  
Conclusion:  
The AHCL system (at BT 100 mg/dL) helps to reduce hyperglycemia after a missed dinner meal bolus in adults and 
adolescents, the latter in whom glucose control is known to be difficult. 
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Accuracy Assessment of the New GlucoMen® 
Day CGM System in Individuals with Type 1 
Diabetes  
 
Amra Simic, MA; Marlene Taucher; Daniel Hochfellner, MD; Maray Dietrich; Tina Pöttler; Felix 
Aberer, MD, PhD; Julia K Mader, MD 
 
Medical University of Graz 




The GlucoMen® Day CGM (WaveForm® Cascade) is a state-of-the-art continuous glucose monitoring (CGM) 
system designed for needle-free insertion that delivers one glucose reading every minute for up to 14 days [recently 
launched by A. Menarini Diagnostics (Italy)]. The objective of the present study is to assess the GlucoMen® Day 
CGM system accuracy against a laboratory reference instrument. 
 
Method 
Eight individuals with type 1 diabetes (N=3 female, mean age: 41.6 ± 13.3 years, BMI 28.0 ± 6.1 kg/m2, A1c 55.6 ± 
12.2 mmol/mol, diabetes duration 13.9 ± 6.5 years) used the GlucoMen® Day CGM system under routine conditions 
for a period of two weeks. Each subject had two CGM systems inserted simultaneously into the subcutaneous tissue 
of the abdomen where they remained for the full fourteen days. On days four and ten, a 5-hour meal/insulin 
challenge test was performed at the clinic to assess the CGM system performance during rapid glucose excursions. 
The serum glucose concentration was determined at the bedside in 20-minute intervals with a glucose oxidase 
reference method (YSI 2300 Stat Plus). The GlucoMen® Day CGM system accuracy was assessed by calculating the 
overall median absolute relative difference (MARD) and the mean absolute difference (MAD), and by performing 
the Consensus Error Grid analysis. 
 
Result 
The MARD and the MAD calculated for the two days spent at the clinic were 9.7 (2.6-14.6)% and 20.5 (9.5-24.0) 
mg/dL, respectively. The Consensus Error Grid analysis showed that 98% of data points were in the clinically 
acceptable zones A and B. 
 
Conclusion 
The study data indicate that in terms of accuracy the GlucoMen® Day CGM system meets the current clinical 
requirements for the state-of-the-art continuous glucose monitors.  
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Differences in Perceived Quality of Sleep and 
Satisfaction with Insulin Delivery Device in 
People with Diabetes 
 
Harsimran Singh, PhD; Michelle Manning, MA; Haidee Sanchez, BS; Keaton Stoner, BS; Steph Habif, 
EdD 
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Poor sleep quality can impair glycemic control in people with diabetes (PwD). It is important to understand factors 
affecting sleep-related outcomes in PwD. However, we know little about sleep-related implications of new-age 
diabetes management devices. 
 
Method: 
PwDs from a diabetes research company’s 2019 US-based panel were invited to participate in this IRB-exempt 
study. Participants with type 1 (T1D) or type 2 diabetes using insulin completed surveys including items on 
perceived quality of sleep (QoS) and satisfaction with their insulin delivery device (IDD).  
 
Result:  
Sample included n=763 PwDs [88% Caucasian, 71% T1D, 64% female, mean age = 51.95 (SD=17.37), mean  
diabetes duration = 24.53 years (SD=14.7)]. For IDD, participants were using multiple daily injection (MDI, 
n=394), patch pump (Omnipod® System, n=155), predictive low glucose suspend system (PLGS) (t:slim X2™ 
Pump with Basal-IQ™ technology, n=117) or hybrid closed-loop system (HCL) (MiniMed™ 670G System, n=97). 
Analysis of variance demonstrated differences in QoS across IDDs, with PLGS users reporting higher perceived 
QoS (mean=8.93, SD=1.69) vs. other IDD users (p<.001). MDI users reported the lowest perceived QoS 
(mean=6.81, SD=2.42). PLGS users reported higher IDD-related satisfaction (mean=8.84, SD=1.17) compared to 
other participants (p<.001). HCL users reported the lowest satisfaction (mean=7.53, SD=1.94). Multiple regression 
revealed perceived QoS as a significant predictor of IDD-related satisfaction (β=.13, p<.001). Qualitative analysis of 
open-ended questions on IDD-related satisfaction and trust highlighted other features valued by participants, 
including convenient software updates, user-friendly data uploads, and ability to use the device discreetly.   
 
Conclusion: 
Results demonstrate a notable relationship between IDD type and QoS. Discussion around sleep-related implications 
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Smart Insulin Pens Allows Correction Doses 
as Needed Without Compromising Time 
Below Range   
 
Madison Smith, PhD, CDCES; Sneha Thanasekaran, MS; Glen Im, MS; Angela Gaetano, MS; 
Janice MacLeod, MA, RD, CDCES, FADCES 
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Smart Insulin Pen (SIP) features allow opportunities to safely deliver more frequent rapid-acting insulin doses. 
Previous research shows that as the number of rapid-acting injections per day increases, Time in Range (TIR) 
improves while maintaining clinical recommendations for Time Below Range (TBR). The purpose of this research 
is to describe the dosing behaviors of SIP users who inject more frequently and their likelihood to deliver correction-
only doses when needed between meals.  
   
Method: 
Real-world clinical data from pediatric and adult SIP users (InPen, Companion Medical) were used to determine the 
frequency of delivering correction-only doses. Users included in the analysis required at least 60 days of paired 
InPen and continuous glucose data available from January through August of 2020. Users were categorized into six 
groups based on the average number of injections per day (>/= 1 through >/= 6). The frequency of users delivering 
correction only doses (vs. doses with meals) was compared across groups.  
 
Result: 
An analysis of N=2,816 users demonstrated a significant increase in the frequency of delivering correction-only 
doses by users who dose more per day (43% for users with >6 doses/day) compared to those who dose less 
frequently (28-33% for users with 1 to < 4 doses/day), while maintaining TBR within clinical guidelines (2.8%).  
 
Conclusion: 
These findings suggest that users who dose more frequently are more likely to correct high glucose values between 
meals. This research supports the use of SIPs to challenge the multiple daily injection (MDI) clinical paradigm of 
only dosing at mealtime to avoid the risk of insulin stacking and hypoglycemia.  
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Measurement of circulating insulin levels is a promising method for improving glycemic management for patients 
with diabetes by allowing determination of individual insulin-glucose dose response relationships. Co-monitoring of 
insulin and glucose could reduce a patient's chances of hypoglycemia and enhance dosing control. Clinical 
immunoassays are available for insulin but require expensive equipment, and there is currently no insulin 
monitoring device on the consumer market. We propose a mass manufacturable point-of-care (POC), 
electrochemical sensor to rapidly measure blood insulin concentration, giving patients and clinicians a more 
accurate way to determine proper insulin dosing when combined with glucose monitoring. Work conducted will aim 




Sensors were prepared by immobilizing a self-assembling monolayer onto a gold screen printed electrode followed 
by attaching a monoclonal insulin antibody. Using electrochemical impedance spectroscopy and a (Fe(CN)6)3- redox 
probe, a calibration curve was generated over the range of 0-2000 pM and validated with ELISA. 
  
Result: 
The imaginary impedance response of the antibody based, gold screen printed calibration curve has an R-squared of 
0.95 with a slope of 21.4 mOhm/(pM) and an optimal frequency of 3125 Hz. Sensors have been tested to be under 
15% coefficient of variance on benchtop studies with purified insulin solution. 
  
Conclusion: 
Current results support the feasibility of a development of POC insulin sensor. The sensor's application towards 
continuous sensing needs to be further developed due to insulin antibody high binding affinity. Future work will 
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Giving teens the ability to understand and optimally manage their type 1 diabetes mellitus (T1DM) will improve the 
quality of their school experience while improving their long-term health outcomes. This ongoing project co-
designs, co-develops, and co-evaluates personalized user-focused information and communications technologies 
(ICTs) to enhance co- and self-management of T1DM for teenagers in the education setting. 
 
Method: 
We are collaborating with 12–17-year-olds, carers, and school representatives in the home and school environment 
to develop an ICT platform to support safe management of T1DM in schools that meets adolescents’ needs and 
preferences, attracts long term use through “stickiness”, and is a valuable source of diabetes management knowledge 
for school-based carers. 
 
Result: 
Our initial experiments have enabled the development of proof-of-concept, consumer-friendly, communication and 
information sharing tools for T1DM management. This involves an individualized online Diabetes School 
Management Plan, linked to a mobile App and web search engine, to help young people and schools to optimally 
manage diabetes. User study findings are informing the creation of “hypothetical” scenarios, which could derail self-
management, and realistic-yet-synthetic annotated resources for ICT development and evaluation. These resources 
will enable us to challenge software developers, researchers, and students to submit solutions to a hackathon in 
2020–2021, which will be evaluated by teenagers, their carers, and health professionals. 
 
Conclusion: 
Our outcomes will inform the next stage of developing ICTs for teens and schools. These, in turn, will enable better 
management of T1DM in education environments, improving the quality of life of affected adolescents, and reduced 
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Insulin, Not the Preservative m-Cresol, 
Instigates Loss of Infusion Site Patency Over 
Extended Durations of CSII in Diabetic 
Swine 
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Insulin infusion sets worn for greater than 4-5 days have been associated with a greater risk of unexplained 
hyperglycemia. We examined the role of the preservative m-cresol in inflammation and changes in infusion site 
patency when infusion sets are worn for extended periods of time in a diabetic swine model. 
  
Method: 
In this cross-over study, insulin pharmacokinetics (PK) and glucose pharmacodynamics (PD) were measured on 
delivery of a bolus of regular human insulin U-100, formulated either with or without 2.5 mg/mL m-cresol, in N=17 
fasted diabetic swine, following 0, 3, 5, 7, and 10 days of continuous subcutaneous insulin infusion (CSII). In a 
subsequent study in the same animals, biopsies were collected and evaluated from swine wearing infusion sets 
infusing (a) nothing, (b) saline, (c) regular human insulin U-100 with 2.5 mg/mL m-cresol, or (d) regular human 
insulin U-100 with no m-cresol, following 3, 7, and 10 days of CSII. 
  
Result: 
Exposure to m-cresol did not result in a statistically significant impact to any PK or PD endpoints. PK and PD 
responses dropped markedly from Day 7 to Day 10, regardless of the presence of m-cresol. Histopathology results 
suggest an additive inflammatory response to both the infusion set and the insulin protein itself, with inflammation 
peaking at Day 7 and remaining stable beyond, and no discernable effect due to the preservative. 
  
Conclusion: 
The preservative m-cresol was not found to contribute to either inflammation or changes in PK/PD endpoints over 
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Virtual health coaching platforms, in which care teams provide remote monitoring or guidance, are an increasingly 
popular means of supporting patients between healthcare provider visits. This study investigated the potential for 
health coaching apps to address barriers to diabetes management and improve patient-reported health outcomes.  
 
Method: 
N=4,962 type 1 and type 2 diabetes patients from an opted-in US research panel were surveyed. A total of N=126 
respondents currently use virtual health coaching apps, and another N=211 have used them in the past.  
 
Result:  
Patients who use health coaching apps are more likely to face barriers to diabetes management like lack of access to 
diabetes specialists (14%) and lack of insurance coverage for preferred therapies (27%), compared to those using 
health apps without coaching (6%, 16%), or not using health apps (8%, 15%).  Those who used health coaching apps 
for over one year are more likely to report decreased A1c (59%) compared to those who used health coaching apps 
for 3-12 months (27%) and 3 months or less (13%). Those with a tenure of 3-12 months were more likely to report 
increased exercise levels (51%) and less likely to experience no benefits (16%), compared to those with a tenure of 3 
months or less (20%, 38%).  Of the patients who explained why they stopped using health coaching apps, 11% 
report cost-related reasons, while 19% found the programs too time-consuming.  
 
Conclusion: 
Patients receiving virtual health coaching are less likely to have access to healthcare and support in their diabetes 
management. As long-term health coaching app usage is associated with improved health outcomes, increasing 
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We have developed an innovative blood glucose control technology based on intravenous (IV) blood sampling and 
delivery of insulin. Compared to current subcutaneous technologies, the IV pathway enables more accurate 
measurements and faster insulin effect. In this work, we present the effect of the IV pathway, combined with a PID 
controller, on maintaining the glucose level within the narrow glycemic range (70-140 mg/dl) for type 1 diabetes in 
silico subjects. Given the reduced delays, no prior meal or activity information is required. 
  
Method: 
The simulations were performed on two in silico type 1 diabetes subject models: the UVa/Padova T1DMS model 
(N=33 subjects) and the NudgeBG model (N=1000 subjects, including the effect of unmeasured sources of variation 
such as stress and exercise). For each subject, glucose profiles were simulated for two days involving four meals/day 
(three main meals and a late-evening snack; 20-70 grams of carbohydrates/meal). Measurement and insulin delivery 
errors were included in the simulation. The control interval was 15 minutes. 
  
Result: 
UVa/Padova T1DMS model - blood glucose median: 115.40 mg/dl (Q25=108.78, Q75=124.93); time in the 70-140 
mg/dl range: 87.71%; time in the 70-180 mg/dl range: 97.03%; time below 70 mg/dl: 0.85%;time above 140 mg/dl: 
11.42%. 
NudgeBG model - blood glucose median: 118.40 mg/dl (Q25=110.96, Q75=129.62); time in the 70-140 mg/dl range: 
81.54%; time in the 70-180 mg/dl range: 93.31%; time below 70 mg/dl: 0.33%; time above 140 mg/dl: 18.12%. 
  
Conclusion: 
The simulations show that IV blood sampling for glucose measurement and IV insulin delivery, combined with a 
closed-loop PID controller, provide effective blood glucose management. It provides high time in range and reduced 
hypoglycemia risk, without requiring meal or physical activity announcement.   
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Morbidity and mortality caused by COVID-19 are unevenly distributed. We sought to correlate county-specific 
COVID-19 mortality with changes in a CGM-based metric of glycemic control. 
 
Method: 
Data were from a convenience sample of US-based users of the G6 CGM System (Dexcom, Inc., San Diego, CA) 
with known residential postal codes. Users resided in counties having at least 1 death attributed to COVID-19 as of 
May 21 and included at least N=200 G6 users. In addition, users had to have uploaded ≥200 glucose values/day for 
≥8 weeks in the pre-pandemic and intra-pandemic intervals (defined as the eight weeks ending on 3/1/2020 and 
6/14/2020, respectively). County-level COVID-19 mortality figures as of May 21, 2020 were aggregated by and 
obtained from the New York Times. Time in range (TIR) was the percentage of glucose values in the 70-180 mg/dL 
range. Within each county, the proportion of individuals who experienced a TIR increase of at least 5 percentage 
points between pre-pandemic and intra-pandemic intervals was calculated.   
 
Result: 
A total of N=35,274 G6 users from 100 counties or county-equivalents provided data. The highest mortality was 
20,491 in the five counties comprising New York City. The proportion of G6 users experiencing at least a 5% 
improvement in TIR ranged from 24.8% (Douglas, Nebraska) to 42.0% (Wayne, Michigan). This proportion and the 
logarithm of COVID-19 mortality were positively correlated (r=0.40, p<0.001); counties with more COVID-19 
deaths tended to have more patients with clinically meaningful improvements in TIR.  
 
Conclusion: 
The local burden imposed by the COVID-19 pandemic may be associated with local changes in behaviors or 
diabetes management strategies that improve the adequacy of glycemic control.  
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Global disruptions in the early months of the COVID-19 pandemic are reflected in changes to diabetes management 
strategies among users of continuous glucose monitoring (CGM) systems. We examined time in range (TIR) before 
and during the pandemic in areas with different median incomes. 
 
Method: 
Pre-pandemic and intra-pandemic observation windows were defined as the four weeks ending on February 16 and 
May 17, 2020, respectively. TIR was defined as the percentage of sensor glucose values in the 70-180 mg/dL range. 
Data were from US-based users of the Dexcom G6 CGM system (Dexcom, Inc., San Diego, CA) with known ZIP 
codes who had uploaded data on or before January 1, 2020, who had uploaded ≥1 value/month in the first 5 months 
of 2020, and who had uploaded ≥200 values/day for ≥4 days/week in both the pre-pandemic and intra-pandemic 
observation windows. Groups of ZIP codes were established based on 2018 estimates of median household income 
(bins ranging from <$50,000 to ≥$150,000), poverty rates (bins ranging from <5% to ≥30.1%), and Gini index (a 
measure of income inequality; bins ranging from <0.4 to >0.5). 
 
Result: 
TIR improved from the pre-pandemic to the intra-pandemic observation window regardless of median income level, 
poverty rate, or Gini index. Intra-pandemic TIR in areas with the lowest median income, highest poverty, and lowest 
income inequality were significantly lower than pre-pandemic TIR in areas with the highest income, lowest poverty, 
and highest income inequality. 
 
Conclusion: 
Although the early months of the COVID-19 pandemic were associated with improved TIR, the magnitude of 
improvement was outweighed by differences associated with income and wealth inequality. CGM can provide 
population-level insights into the adequacy of glycemic control.   
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Objective: 
A1C is used to gauge the level of outpatient glycemic control when determining an inpatient antihyperglycemic 
regimen. We evaluated concordance between observed average glucose (OAG) and A1C-estimated average glucose 
(eAG) in hospitalized patients with diabetes. 
  
Method:  
Retrospective analysis was performed using N=937,837 blood glucose measurements from N=17,903 unique adult 
patients over five years. The ratio of OAG to eAG was used to identify patient phenotypes based on percentile: 
concordant (within IQR), observed less than expected (<25th percentile), and observed greater than expected 
(>75th percentile). Multivariable logistic regressions were used to evaluate clinical, patient, and hospital factors 
associated with either discordant phenotype. 
  
Result:  
Factors (adjusted OR; 95% CI) associated with lower OAG than eAG include: female sex (1.09; 1.00-1.18), black 
race (1.68; 1.54-1.83), higher hemoglobin (1.11; 1.09-1.14), higher total daily insulin dose (1.01; 1.00-1.01), 
carbohydrate-controlled diet (1.39; 1.27-1.52), NPO/liquid diet (1.18; 1.04-1.34), and taking home insulin (1.27; 
1.16-1.39). Factors associated with higher OAG than eAG include: discharge from Intermediate Care Unit (1.21; 
1.07-1.37), discharge from a surgical or procedural unit (7.37; 1.18-46.02), higher systolic blood pressure (1.01; 
1.00-1.01), tachycardia (1.22; 1.12-1.33), higher respiratory rate (1.04; 1.02-1.06), higher potassium (1.08; 1.02-
1.14), higher total daily insulin dose (1.00; 1.00-1.01), and high steroid dose (2.82; 2.50-3.18).  
  
Conclusion:  
Inpatient glucose levels are lower than expected based on A1C in women, blacks, patients on carbohydrate-
controlled or NPO/liquid diets, and those receiving home insulin or higher inpatient insulin doses.  Conversely, 
inpatient glucose levels are higher than expected in patients admitted to surgical or intermediate care units, those 
receiving high dose steroids or higher insulin doses, and those with higher potassium levels or vital sign indicators 
of more severe illness.   
 
  
A474 Journal of Diabetes Science and Technology 15(2)DTM 2020 Abstracts  A78 
 
One- to Six-Month Forecasts of Time-in-
Range 
 
Ydo Wexler, PhD; Dan Goldner, PhD; Brian Huddleston, JD; Jeff Dachis, MA  
 
One Drop 




Time-in-range is increasingly of interest as a metric of diabetes management. Accurate predictions of changing 
time-in-range can support timely delivery of treatment and lifestyle recommendations, leading to improved 
outcomes. We used continuous glucose monitoring (CGM) data and other health and self-care data collected in the 
One Drop app to forecast individual’s changes in 30-day time-in-range from one to six months in advance. 
  
Method: 
Data were used to train a suite of patent-pending supervised machine learning models, each for a different time 
horizon: 1-2, 2-3, 3-4, or 4-6 months. Data collected prior to 2019 were used for training; data from January 2019 
through February 2020 were used for testing. The test set comprised over 67,000 predictions. Prediction root mean 
square error (RMSE) was compared to the RMSE that would result from assuming persistence (no change from 
current values). Population subsets were identified, based on information available at prediction time, for whom 
predictions were more accurate.  
  
Result: 
Error reduction relative to persistence varied by forecast horizon and population subset. For 30-day time-in-range, 
persistence RMSE ranged from 12.1-17.6%, while model RMSE ranged from 7.1-11.8%. Error reductions ranged 
from 22.2-41.2% relative to persistence.  
  
Conclusion: 
Machine learning models based on app-collected CGM, health, and self-care data can predict changes in time-in-
range up to six months in advance. These predictions can contribute to prioritizing interventions and guiding self-
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Translation of diabetes self-management education and support (DSMES) into a digital format can improve access, 
but few digital programs have demonstrated outcomes using rigorous evaluation metrics. This pilot shares early 
insights into the impact of a digital DSMES program on glycemic control for type 2 diabetes. 
 
Method: 
A single-arm, non-randomized trial was conducted to evaluate a digital DSMES program that includes remote 
monitoring and lifestyle change, in addition to comprehensive diabetes education, staffed by a diabetes specialist. A 
sample of N=195 participants were virtually recruited using an online research platform. The primary outcome was 
change in laboratory-tested hemoglobin A1c from baseline to 4 months, and secondary outcomes included change in 
lipids, diabetes distress, and medication adherence. 
 
Result: 
At baseline, participants had a mean A1c of 8.9% (SD=1.9) and mean BMI of 37.5 kg/m2 (SD=8.3). The average age 
was 45.1 years (SD=8.9), 70% were women, and 72% were White. At 4-month follow-up, the A1c decreased by 
0.8% (p=.001, 95% CI [-1.1, -0.5]) for the total population and decreased by 1.4% (p=.001, 95% CI [-1.8, -0.9]) for 
those with worse glucose control at baseline (A1c = 9.0%+). Diabetes distress and medication adherence were also 
significantly improved between baseline and follow-up. 
 
Conclusion: 
This study provides early evidence that a digitally enhanced DSMES program improves glycemic control and 
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During type 1 diabetes (T1D) pump therapy, an insulin infusion set (IIS) with varied cannula length may be placed 
in the abdomen, arm, thigh, or buttocks based on personal preference. In this work, the impact of IIS site selection 
on IIS wear duration and total daily insulin dose (TDD) was assessed in a pre-clinical T1D porcine model and the 
effect of cannula length with the same characteristics was evaluated in two adult T1D clinical trials.  
 
Method: 
In the T1D porcine studies, an IIS with 43” tubing was placed in the dorsum (skin-thickness 3.5-5µm, n=24) or 
abdomen (skin-thickness 2.8-3.4µm, n=56). Insulin was infused for glycemic control for up-to 7 days.  In two adult 
T1D clinical trials, an IIS with 43” tubing and 6-mm (total n=43) or 9-mm (total n=143) cannula was worn primarily 
in the abdomen (>90%) with insulin infused for glycemic control for up-to 7 days. The IIS wear duration and mean 
TDD were determined for both the pre-clinical and clinical studies. 
 
Result: 
In the porcine model, there was no significant difference between the IIS survival curves for the dorsum and the 
abdomen locations. However, TDD was significantly greater in the dorsum (25-30 U/day) compared to the abdomen 
(15-20 U/day). In both clinical trials, survival curves of the IIS with 6-mm and 9-mm cannula showed no significant 
difference. However, TDD over 7 days (43.8-48.1 U/day) in the 9-mm group was more stable over time with smaller 
day-to-day variations, compared to the TDD in the 6-mm group (45.8-54.6 U/day).    
 
Conclusion: 
These data indicate that cannula length & site selection may play a significant role in TDD. Additional studies are 
required to make more definitive conclusions. 
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Performance of a Factory-Calibrated 
Continuous Glucose Monitoring (CGM) 
System with a Retuned Algorithm 
 








The algorithm of a factory-calibrated CGM system (Dexcom G6) was retuned to improve data availability. Its 
performance was assessed by reprocessing raw data from a large clinical trial. 
 
Method: 
Participants ages 6+ years with insulin-treated diabetes were enrolled at 11 U.S. sites to assess Dexcom G6 CGM 
system performance (NCT02880267). In-clinic visits for frequent comparative blood glucose measurements using 
YSI were conducted on days 1, 4-5, 7, and/or 10 of system use and varied in length based on participant age. Raw 
sensor data were reprocessed with the retuned algorithm. Accuracy evaluation included the proportion of CGM 
values that were within ±20% of YSI reference value for glucose levels ≥70 mg/dL and ±20 mg/dL for YSI glucose 
levels <70 mg/dL (%20/20) as well as the mean absolute relative difference (MARD) between temporally matched 
CGM and YSI values. Data availability was calculated by capturing the frequency of intermittently missed readings 
for sensors that lasted the full sensor wear period. 
 
Result: 
Three hundred eighty participants enrolled and N=325 were included in the performance evaluation. There was a 
1.4% increase in percentage of sensors with more than 90% of readings with the retuned algorithm compared to the 
original algorithm. Overall performance was retained: with the new algorithm, %20/20 overall, for adults, and for 
children ages 6-17 years was 91.8%, 91.8%, and 92.0%, respectively, compared to 91.7%, 91.6%, and 92.0%  for 




Modifications to the algorithm of a factory-calibrated CGM system improved data availability without substantially 
affecting system performance. Increased data availability may improve patient experience and may allow CGM data 
incorporation into automated insulin delivery systems.  
 
 
 
